UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐ | Preliminary Proxy Statement |
☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
☒ | Definitive Proxy Statement |
☐ | Definitive Additional Materials |
☐ | Soliciting Material under §240.14a-12 |
The Cooper Companies, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
☒ | No fee required |
☐ | Fee paid previously with preliminary materials |
☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
January 30, 2023
Dear Stockholder:
You are cordially invited to join us at the 2023 Annual Meeting of Stockholders (the Annual Meeting) of The Cooper Companies, Inc. (the Company or Cooper), which will be held at 8:00 a.m. (Pacific Time) on March 15, 2023, at our corporate headquarters at 6101 Bollinger Canyon Road, Suite 500, San Ramon, California.
At the Annual Meeting we will ask our stockholders to vote on the proposals detailed in our Proxy Statement and related materials. We will be providing access to our proxy materials electronically under the U.S. Securities and Exchange Commissions notice and access rules. As a result, beginning on or about February 3, 2023, we are mailing a Notice of Internet Availability of Proxy Materials (the Notice) to many of our stockholders instead of paper copies of this Proxy Statement and our Annual Report on Form 10-K for the year ended October 31, 2022 (the 2022 Annual Report). This approach conserves natural resources and reduces our printing and distribution costs, while providing a timely and convenient method of accessing the materials and voting.
The Notice contains instructions on how to access our materials through the internet and also contains instructions on how to receive a paper copy of our proxy materials, including the Proxy Statement, the 2022 Annual Report, and a form of proxy card or voting instruction card. All stockholders who do not receive a Notice, including stockholders who have previously requested to receive paper copies of proxy materials, will receive a paper copy of the proxy materials by mail.
Your vote is important. Regardless of whether you plan to attend the Annual Meeting, we hope you will vote as soon as possible. You may vote by proxy by following the instructions on the proxy card or voting instruction card. Voting may be done over the internet, by telephone, or by mail (if you received paper copies of the proxy materials). Voting by proxy will ensure your representation at the Annual Meeting.
We look forward to seeing you at the Annual Meeting.
Sincerely,
Robert S. Weiss
Chairman of the Board of Directors
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
![]() |
6101 Bollinger Canyon Road, Suite 500 San Ramon, CA 94583 |
Meeting Date: |
Wednesday, March 15, 2023 | |
Meeting Time: |
8:00 a.m. (Pacific Time) | |
Location: |
CooperCompanies Headquarters 6101 Bollinger Canyon Road, Suite 500 San Ramon, California 94583 | |
Admission: |
All stockholders are cordially invited to attend the Annual Meeting in person. | |
Agenda: |
1. Elect eight directors to our Board. 2. Ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending October 31, 2023. 3. Approve the 2023 Long-Term Incentive Plan for Employees. 4. Hold an advisory vote on the compensation of our Named Executive Officers (Say on Pay Proposal). 5. Hold an advisory vote on the frequency of presentation of the Say on Pay Proposal. 6. Transact any other business that may properly come before the meeting. |
Stockholders of record at the close of business on Thursday, January 19, 2023, or their legal proxy holders, will be entitled to vote at the Annual Meeting.
On or about February 3, 2023, we will mail either (1) a Notice of Internet Availability of Proxy Materials or (2) a copy of this Proxy Statement and our Annual Report for the fiscal year ended October 31, 2022. The Notice will also contain instructions on how to request a paper copy of our proxy materials.
You may vote by following the instructions on the Notice or by using the proxy card accompanying the paper copy of materials. If phone or internet voting is available to you, instructions will be included on your proxy card.
YOUR VOTE IS IMPORTANT TO US. Regardless of whether you plan to attend the Annual Meeting, we encourage you to vote your shares as soon as possible to ensure that your vote is recorded. We look forward to your participation.
By Order of the Board of Directors of
THE COOPER COMPANIES, INC.
Nicholas S. Khadder
Vice President, General Counsel, and Secretary
Dated: February 3, 2023
1 | ||||
2 | ||||
4 | ||||
4 | ||||
5 | ||||
5 | ||||
7 | ||||
8 | ||||
9 | ||||
10 | ||||
11 | ||||
13 | ||||
16 | ||||
17 | ||||
19 | ||||
21 | ||||
40 | ||||
41 | ||||
51 | ||||
52 | ||||
54 | ||||
PROPOSAL 2 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM |
63 | |||
65 | ||||
PROPOSAL 4 ADVISORY VOTE ON NAMED EXECUTIVE OFFICER COMPENSATION |
75 | |||
77 | ||||
78 | ||||
82 | ||||
83 | ||||
1-A |
2023 ANNUAL MEETING OF STOCKHOLDERS
Date and Time: |
Wednesday, March 15, 2023 at 8:00 a.m. (Pacific Time) | |
Location: |
6101 Bollinger Canyon Road, Suite 500 | |
San Ramon, California 94583 | ||
Notice Mailing Date: |
February 3, 2023 | |
Record Date: |
January 19, 2023 |
This Proxy Statement is presented on our behalf by order of the Board of Directors (the Board). It contains information about our Company and the proposals to be presented at the Annual Meeting.
Throughout this Proxy Statement, we may also refer to various documents that are available on our website. The content posted on, or accessible through, our website is not incorporated by reference into this Proxy Statement or any of our filings with the U.S. Securities and Exchange Commission (the SEC) and may be revised by us (in whole or in part) at any time and from time to time.
We have also furnished our 2022 Annual Report to all stockholders of record. The 2022 Annual Report contains our financial statements for the fiscal year ended October 31, 2022 and other useful information, but it is not part of the materials for the solicitation of proxies.
WE STRONGLY ENCOURAGE YOU TO VOTE
|
Page | 1
Proposals to Be Presented at the Annual Meeting
PROPOSAL 1 ELECTION OF DIRECTORS |
|
PAGE 54 |
BOARD RECOMMENDATION: |
✓ FOR EACH DIRECTOR |
|||
VOTE REQUIREMENT: |
MAJORITY OF VOTES CAST |
YOU ARE BEING ASKED TO VOTE ON THE ELECTION OF THE EIGHT DIRECTORS LISTED BELOW.
Each director nominee is elected annually. Additional information about all current directors and selection of nominees can be found beginning on page 5. Information about the nominees and their qualifications for service can be found beginning on page 54.
Director Nominees for Consideration at the Annual Meeting
COMMITTEE MEMBERSHIPS | ||||||||||||||||||||||||||||||
NAME | DIRECTOR SINCE |
AGE | AUDIT | CORPORATE GOVERNANCE & NOMINATING |
ORGANIZATION &
COMPENSATION |
INDEPENDENT | ||||||||||||||||||||||||
Robert S. Weiss (Chairman) |
1996 | 76 | ✓ | |||||||||||||||||||||||||||
William A. Kozy (Lead Director) |
2016 | 71 | ❖ | ◆ | ✓ | |||||||||||||||||||||||||
Colleen E. Jay |
2016 | 60 | ◆ | ❖ | ✓ | |||||||||||||||||||||||||
Cynthia L. Lucchese |
2022 | 62 | ◆ | ◆ | ✓ | |||||||||||||||||||||||||
Teresa S. Madden |
2020 | 66 | ❖ | ◆ | ✓ | |||||||||||||||||||||||||
Gary S. Petersmeyer |
2013 | 75 | ◆ | ◆ | ✓ | |||||||||||||||||||||||||
Maria Rivas, M.D. |
2021 | 59 | ◆ | ◆ | ✓ | |||||||||||||||||||||||||
Albert G. White III (CEO) |
2018 | 53 | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PROPOSAL 2 RATIFY APPOINTMENT OF KPMG LLP | PAGE 63 |
BOARD RECOMMENDATION: |
✓ FOR |
|||
VOTE REQUIREMENT: |
MAJORITY OF VOTES CAST |
YOU ARE BEING ASKED TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM.
The Audit Committee has appointed the firm of KPMG LLP (KPMG) to act as our independent registered public accounting firm and to audit our consolidated financial statements for the fiscal year ending October 31, 2023. This appointment will continue at the pleasure of the Audit Committee and is presented to the stockholders for ratification as a matter of good governance.
Page | 2
PROPOSAL 3 APPROVAL OF THE 2023 LONG-TERM INCENTIVE PLAN | PAGE 65 |
BOARD RECOMMENDATION: |
✓ FOR |
|||
VOTE REQUIREMENT: |
MAJORITY OF VOTES CAST |
YOU ARE BEING ASKED TO APPROVE THE 2023 LONG-TERM INCENTIVE PLAN TO
PROVIDE FOR EQUITY-BASED COMPENSATION FOR OUR EMPLOYEES.
The 2023 Long-Term Incentive Plan replaces the Third Amended & Restated 2007 Long-Term Incentive Plan and will provide for awards of stock options, restricted stock units, performance-based equity, and other equity based awards.
Information regarding our compensation practices and the compensation of our Named Executive Officers in the 2022 fiscal year can be found in our Compensation Discussion and Analysis starting on page 21 and the following compensation tables.
Additional information regarding the 2023 Long-Term Incentive Plan can be found starting on page 65.
PROPOSAL 4 ADVISORY VOTE ON EXECUTIVE COMPENSATION (SAY ON PAY) | PAGE 75 |
BOARD RECOMMENDATION: |
✓ FOR |
|||
VOTE REQUIREMENT: |
MAJORITY OF VOTES CAST |
YOU ARE BEING ASKED TO VOTE, ON AN ADVISORY BASIS, ON THE COMPENSATION OF OUR NAMED
EXECUTIVE OFFICERS
Information regarding our compensation practices and the compensation of our Named Executive Officers in the 2022 fiscal year can be found below in our Compensation Discussion and Analysis starting on page 21 and the following compensation tables.
Named Executive Officers for Fiscal 2022
Name | Title | |
Albert G. White III |
President & Chief Executive Officer | |
Brian G. Andrews |
Executive Vice President, Chief Financial Officer & Treasurer | |
Daniel G. McBride |
Executive Vice President & Chief Operating Officer | |
Holly R. Sheffield |
President, CooperSurgical, Inc. | |
Gerard H. Warner III |
President, CooperVision, Inc. | |
|
|
PROPOSAL 5 ADVISORY VOTE ON FREQUENCY OF SAY ON PAY VOTE | PAGE 77 |
BOARD RECOMMENDATION: |
✓ ANNUALLY |
|||
VOTE REQUIREMENT: |
PLURALITY OF VOTES CAST |
YOU ARE BEING ASKED TO VOTE, ON AN ADVISORY BASIS, ON THE FREQUENCY WITH WHICH THE COMPANY
SEEKS AN ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
Page | 3
COMMITTEE MEMBERSHIPS | |||||||||||||||||||||||||||||||||||
CURRENT DIRECTORS | DIRECTOR SINCE |
AGE | AUDIT | CORPORATE GOVERNANCE & NOMINATING |
ORGANIZATION & COMPENSATION |
INDEPENDENT | OTHER PUBLIC BOARDS | ||||||||||||||||||||||||||||
Robert S. Weiss (Chairman) |
1996 | 76 | ✓ | -- | |||||||||||||||||||||||||||||||
William A. Kozy (Lead Director) |
2016 | 71 | ❖ | ◆ | ✓ | 1 | |||||||||||||||||||||||||||||
Colleen E. Jay |
2016 | 60 | ◆ | ❖ | ✓ | 2 | |||||||||||||||||||||||||||||
Jody S. Lindell (1) |
2006 | 71 | ◆ | ◆ | ✓ | -- | |||||||||||||||||||||||||||||
Cynthia L. Lucchese |
2022 | 62 | ◆ | ◆ | ✓ | 2 | |||||||||||||||||||||||||||||
Teresa S. Madden |
2020 | 66 | ❖ | ◆ | ✓ | 1 | |||||||||||||||||||||||||||||
Gary S. Petersmeyer |
2013 | 75 | ◆ | ◆ | ✓ | -- | |||||||||||||||||||||||||||||
Maria Rivas, M.D. |
2021 | 59 | ◆ | ◆ | ✓ | -- | |||||||||||||||||||||||||||||
Albert G. White III (CEO) |
2018 | 53 | -- | ||||||||||||||||||||||||||||||||
|
❖ - Committee Chair ◆ Committee Member
(1) | Ms. Lindell has announced her intention to retire as a director effective on the date of the Annual Meeting and will not stand for re-election. Additional information about the director nominees can be found starting at page 54. |
DEMOGRAPHICS | ||||||||||||||||
|
WEISS | KOZY | JAY | LUCCHESE | MADDEN | PETERSMEYER | RIVAS | WHITE | ||||||||
RACE/ETHNICITY | ||||||||||||||||
African American |
|
|
|
|
|
|
|
| ||||||||
Asian/Pacific Islander |
|
|
|
|
|
|
|
| ||||||||
Hispanic/Latinx |
|
|
|
|
|
|
◆ |
| ||||||||
Native American |
|
|
|
|
|
|
|
| ||||||||
White/Caucasian |
◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
|
◆ | ||||||||
GENDER | ||||||||||||||||
Male |
◆ | ◆ |
|
|
|
◆ |
|
◆ | ||||||||
Female |
|
|
◆ | ◆ | ◆ |
|
◆ |
| ||||||||
Non-Binary |
|
|
|
|
|
|
|
| ||||||||
TENURE | ||||||||||||||||
Years |
27 | 7 | 7 | 0 | 2 | 10 | 2 | 5 | ||||||||
|
|
|
|
|
|
|
|
|
We maintain separate positions for the Chairman and Chief Executive Officer (CEO). We also maintain an independent Lead Director position. We feel this division provides a balance between the independence of our directors and the experience of our officers. Our current Chairman has significant business experience with the Company but has also been affirmatively determined to be independent by our Board. We feel that maintaining a separation between the Chair and the CEO provides for strong, knowledgeable leadership of the Board separate from the CEOs immediate, day-to-day involvement with the Company.
Page | 4
Meetings
The Board and its committees met as follows during our most recent fiscal year:
|
Number of Meetings | ||||
Board of Directors |
7 | ||||
Audit Committee |
7 | ||||
Organization & Compensation Committee |
5 | ||||
Corporate Governance & Nominating Committee |
4 |
The non-employee directors hold executive sessions in connection with regular meetings of the Board and more often as they deem appropriate. Either Mr. Weiss, as Chair, or Mr. Kozy, as Lead Director, presides over executive sessions.
During the 2022 fiscal year, each director attended at least 75% of the board meetings and meetings of committees on which the director served. Currently we do not maintain a formal policy regarding director attendance at the Annual Meeting.
In making determinations regarding independence, the Board considers the objective requirements for independence set forth by the New York Stock Exchange (NYSE) and the SEC. The Board has confirmed that each independent director has no relationship to the Company, either directly or indirectly, other than as a stockholder of the Company or through their service on the Board. The Board and its committees conduct regular self-evaluations and review director independence and committee composition to ensure continued compliance with applicable regulations.
Additionally, under our Corporate Governance Principles, directors are not permitted to serve on the boards of more than two other public companies while they serve on our Board; provided, that the Board may make exceptions to this standard as it deems appropriate in the interest of our stockholders. We do not limit service on private company boards of directors or with non-profit organizations. The Board considers these affiliations and professional relationships on a case-by-case basis to ensure there are no conflicts of interest with the Company or other factors that would impair the relevant non-employee directors independence from the Company.
The Corporate Governance & Nominating Committee (the CGNC) is responsible for identification and recommendation of qualified candidates to present to the Board for consideration as director nominees. As part of this responsibility, the CGNC annually considers the size, composition, diversity, and responsibilities of the Board. The CGNC considers the background and skills of the current board members, the needs of the Board, and the qualifications of any potential candidates prior to making recommendations regarding nominations.
Stockholder nominations must be received on a timely basis and meet the criteria set forth below and in the information on Stockholder Proposals and Nominations for Director on page 82.
Page | 5
Criteria for Nominees
The CGNC has set minimum criteria which must be met by any director candidate as follows:
(1) | meet the objective independence requirements set forth by the SEC and NYSE (other than executive nominees), |
(2) | exhibit strong personal integrity, character, and ethics, and a commitment to ethical business and accounting practices, |
(3) | demonstrate an understanding of, and commitment to, good governance practices and the fiduciary responsibilities expected of a director, |
(4) | have an appropriate educational background and significant business or professional experience, |
(5) | not serve on more than two other public company boards, |
(6) | not be involved in on-going litigation with Cooper or be employed by an entity which is engaged in such litigation, and |
(7) | not be the subject of any on-going criminal investigations, including investigations for fraud or financial misconduct. |
The CGNC also considers whether a candidate has any special expertise, skills, or background that would be of particular benefit to the Company and whether a candidates background or qualifications will strengthen the overall diversity of the Board. The CGNC seeks candidates who demonstrate an understanding of financial statements and financial matters, offer business and managerial experience that will complement the experience of current directors, and provide additional depth of knowledge in areas that will benefit the Board in its oversight of our business.
Diversity and Inclusion
In addition to these minimum standards, the CGNC believes it is important to have directors from various backgrounds and professions in order to ensure that the Board has a wealth of experiences to inform its decisions. Consistent with this philosophy, the CGNC is committed to including candidates in each search who reflect diverse backgrounds, including, but not limited to, diversity of gender and race.
Board Refreshment
The Board has not adopted formal term limits or retirement age requirements, as it believes these are arbitrary and limit the ability to retain directors with valuable experience and company knowledge. However, the Board is committed to refreshment of the board of directors on a regular basis to ensure a balance of new ideas with experienced leadership.
In furtherance of this commitment, the Board has worked actively to develop internal policies and practices to ensure regular refreshment of appointments, and the CGNC has developed a succession planning framework to ensure continued refreshment of Board appointments.
Three of our current directors joined the Board within the past five years, and over half of our directors have served for no more than ten years. The Board views this as a meaningful advancement of its efforts to refresh its membership and expects to continue these efforts going forward.
Page | 6
The Board currently maintains three standing committees as described below. Committee membership is determined by the Board and reviewed regularly. As required by the SEC and NYSE, all members of our Audit Committee, Corporate Governance & Nominating Committee, and Organization & Compensation Committee (OCC) are independent directors.
Each committee maintains a written charter detailing its authority and responsibilities. These charters are updated periodically as legislative and regulatory developments and business circumstances warrant.
Our committee charters are available in their entirety on our website at http://investor.coopercos.com/corporate-governance.
Audit Committee |
Members | |
The Audit Committee provides advice with respect to our financial matters and assists the Board in fulfilling its oversight responsibilities regarding: (i) the quality and integrity of the Companys financial statements, (ii) the Companys compliance with legal and regulatory requirements, (iii) review of our potential risk factors, (iv) our system of internal accounting and financial controls, (v) our enterprise risk management program, (vi) the qualifications and independence of the independent registered public accounting firm (the Independent Auditors) and (vii) the oversight and performance of the Companys internal audit function and the Independent Auditors.
The Audit Committee advises and makes recommendations to the Board regarding our financial, investment, and accounting procedures and practices. The Audit Committee also has oversight responsibility for treasury and investment matters and the Companys information security programs.
Additional information regarding the Audit Committee and its responsibilities can be found below in the information on Audit Matters starting on page 13.
|
Teresa S. Madden
Jody S. Lindell(1) Cynthia L. Lucchese Gary S. Petersmeyer Maria Rivas, M.D. | |
Organization & Compensation Committee |
Members | |
The OCC reviews and approves all aspects of the compensation paid to our Chief Executive Officer and our executive officers as defined by Rule 3b-7 of the Securities Exchange Act of 1934, as amended (the Exchange Act). Members of the OCC are not eligible to participate in any of our executive compensation programs.
The OCC approves the composition of our peer group for comparative compensation review, the terms of our incentive compensation and equity-based plans (including the allocation and terms of equity awards to employees), corporate goals and objectives for the Chief Executive Officer, and any agreements providing for the payment of benefits following a change in control of the Company. The OCC also advises and makes recommendations to the Board regarding annual compensation of the non-employee directors. The OCC has oversight responsibility for our retirement programs and human capital management practices, including succession planning, diversity & inclusion objectives, and other management development programs designed to strengthen our internal pool of candidates for executive level positions and promote mentoring of senior level employees.
|
Colleen E. Jay
William A. Kozy Teresa S. Madden Gary S. Petersmeyer |
Page | 7
Corporate Governance & Nominating Committee |
Members | |
The CGNC develops, implements, and maintains the corporate governance standards by which we conduct business. The CGNC advises and makes recommendations to the Board concerning our primary governance policies, proposed changes to our charter and by-laws, proposed changes to the charters of the Board committees, and procedures for reporting violations of our corporate governance standards. The CGNC monitors compliance with our Code of Conduct and other policies by our directors and officers and has responsibility for review of any conflicts of interest (actual or potential) and any related party transactions (as defined under Item 404 of Regulation S-K).
The CGNC performs the functions described under Director Nomination Process on page 5 and makes recommendations regarding the composition, function, and size of the Board and its Committees, standards for the Boards review of its own performance, continuing education for directors, and matters related to Board refreshment and succession planning.
The CGNC also oversees our compliance programs and our Environmental, Social and Governance initiatives as discussed in more detail on page 10.
|
William A. Kozy
Colleen E. Jay Jody S. Lindell(1) Cynthia L. Lucchese Maria Rivas, M.D. |
(1) | Ms. Lindell has announced her intention to retire as a director effective on the date of the Annual Meeting and will not stand for re-election. |
We have an ongoing commitment to good governance and business practices. In furtherance of this commitment, we regularly monitor developments in the area of corporate governance and review our policies and practices in light of such developments. We seek to comply with the rules and regulations promulgated by the SEC and the NYSE and implement other corporate governance practices we believe are in the best interest of the Company and its stockholders.
In keeping with this commitment:
| All members of our Board are independent, other than Mr. White (our Chief Executive Officer). |
| All members of the committees of our Board are independent. |
| Board members stand for re-election annually and our corporate Bylaws include a majority voting standard for the election of our directors. |
| Our Bylaws include proxy access provisions. |
| The Board is active in oversight of risk and risk management. |
| We do not maintain a stockholder rights plan (poison pill). |
| We are committed to corporate social responsibility and sustainability. |
Additionally, we maintain various corporate policies, discussed in more detail below, that reflect our dedication to good governance. We believe that the policies and practices currently in place enhance our stockholders interests.
Page | 8
Corporate Governance Principles
We maintain a set of Corporate Governance Principles which specify our standards for director qualifications, director responsibilities, Board committees, director access to our executive officers and employees, director orientation and continuing education, and performance evaluations of the Chief Executive Officer and of the Board and its committees. The Corporate Governance Principles also address compensation and stock ownership requirements for our non-employee directors (discussed in more detail in the section on Director Compensation starting on page 51). The Corporate Governance Principles are available in their entirety on our website at http://investor.coopercos.com/corporate-governance.
Code of Conduct
Our Code of Conduct (the Code) was adopted in June 2021 and replaced our prior Ethics & Business Conduct Policy. The Code is designed to reflect current best practices, enhance and expand on the Companys understanding of ethical business practices, elaborate on certain topics such as human rights, diversity, inclusion, and equality, and promote awareness of ethical issues that may be encountered in carrying out an employees or directors responsibilities.
We have designed the Code to provide guidance regarding compliance with laws, regulations, and Company policies and we regularly communicate with employees regarding the Code to ensure familiarity and awareness. The Code applies to all of our employees, executive officers, and non-employee directors, including our Chief Executive Officer and Chief Financial Officer, and we require that employees annually certify their agreement to abide by the policy.
The Code provides guidance on multiple topics, including: (i) conflicts of interest, (ii) the protection and proper use of Company assets, (iii) relationships with customers, suppliers, competitors, and associates, (iv) government relations and anti-corruption regulations, and (v) compliance with laws and regulations, including laws and regulations relating to insider trading, equal employment opportunity, harassment, and health and safety. We have also added content regarding preventing fraud and money laundering, use of social media, promoting human rights, diversity and equity, and our commitments to environmental and social initiatives. Employees are encouraged to report any conduct that they believe in good faith to be an actual or apparent violation of the Code.
The Code has been translated into multiple languages to facilitate readability and all employees receive a copy of the Code both at their date of hire and annually. The Code is also posted on our internal web pages for ease of access and is available in its entirety on our website at https://investor.coopercos.com/ethics-compliance.
Amendments to the Code, and any waivers from the Code granted to directors or executive officers will be made available through our website. As of the date of this Proxy Statement, no waivers have been requested or granted, and adoption of the new Code did not result in any explicit or implicit waiver of any provision of the Ethics & Business Conduct Policy that was in effect prior to the adoption of the Code.
Stock Trading Policy: Hedging & Pledging
We have implemented a Stock Trading Policy that applies to senior executives, including our Named Executive Officers and all members of the Board of Directors. Under this Policy, trading in Company securities is prohibited except during specifically designated windows. Additionally, executives and members of the Board are prohibited from engaging in various trading practices which would suggest speculation in our securities,
Page | 9
including short sales, puts, calls, forward sales, equity swaps, or other hedging transactions. Our Policy does permit executives and members of the Board to pledge securities as collateral, but only upon prior notice to, and approval from, the Company.
Environmental, Social and Governance (ESG) Initiatives
We believe that conducting business in a socially and environmentally responsible manner is important to our long-term success and the future of our planet. Recognizing the significant impact that ESG issues have on our ability to achieve sustainable growth, we are expanding existing initiatives and actively developing new projects to make sustainability and corporate responsibility a key focus of our business.
To better support these initiatives from the top down, our Board has increased the frequency of ESG discussions at its meetings and the CGNC has oversight responsibility for ESG matters under its charter. In this capacity, the CGNC has general oversight authority for our overall ESG strategy, but specific topics continue to be overseen by other committees as appropriate, including cybersecurity oversight by the Audit Committee and human capital management review by the OCC.
We released our annual ESG Report in May 2022, and it can be found on our public website at https://www.coopercos.com/esg/. The report is designed to provide transparency regarding our ESG efforts, and we encourage you to read it for information regarding our ESG initiatives, activities in furtherance of our commitment to the United Nations Sustainable Development Goals, diversity and inclusion efforts, human capital management, and commitments to data privacy and security.
Highlights from the report include:
| Continued recognition as a great place to work including: |
○ | Earned a score of 100% on the Human Rights Campaign Foundations Corporate Equality Index 2022 |
○ | Named one of Fortune Magazines Top 10 Best Large Workplaces in Manufacturing and Production for the second consecutive year |
| Ongoing development of our diversity & inclusion initiatives, including establishment of a Global Center of Expertise dedicated to D&I within our Human Resources organization |
| Expanded initiatives to reduce our environmental impact including: |
○ | Partnership with PlasticBank to create the first net plastic-neutral contact lens |
○ | Internal initiatives to identify new, lower impact, packaging solutions |
○ | Construction of a new, more efficient, combined heat and power plant for our manufacturing and distribution facility in Puerto Rico |
○ | 100% renewable electricity sourcing at all key facilities in New York and the United Kingdom |
○ | 95% of materials in CooperVisions production processes are recycled |
| Continued and expanded partnerships to support our communities through charitable giving, including partnerships to expand access to eye exams, vision care, and vision correction and programs to assist women with access to critical care during the Covid-19 pandemic. |
In addition to our ESG Report, additional information regarding our corporate responsibility initiatives can be found on our website at http://www.coopercos.com/corporate-responsibility.
Although we encourage our stockholders to review the information in our ESG Report and on our website, the contents of the report and website are not deemed filed with the SEC and are not incorporated by reference into any filing by Cooper under the Exchange Act.
Page | 10
Board of Directors Role in Risk Oversight
General
Our Board of Directors recognizes the importance of appropriate oversight of potential business risks in running a successful operation and meeting its fiduciary obligations to our business and our stockholders. While our management team has responsibility for the day-to-day assessment and management of potential business risks, the Board maintains responsibility for ensuring an appropriate culture of risk management and setting the proper tone at the top.
In this function, the Board, directly and through its committees, takes an active role in overseeing our material risks and risk profile and in assisting management with addressing specific risks, including competitive, legal, regulatory, operational, and financial risks. Each committee of the Board regularly reviews risks related to its area of focus and managements Global Risk Committee provides updates to the Board and Audit Committee regarding key business risks and management efforts to mitigate identified risks.
Cybersecurity Risks
The Audit Committee has oversight authority for our information security programs and receives updates at least quarterly from management on matters related to cybersecurity incidents. Our IT leadership also provides a detailed, in-person update to the Committee annually. This update includes a discussion of significant threats to our systems, risk mitigation strategies, program assessments, planned improvements, and status of information security initiatives.
We have adopted the Center for Internet Security (CIS) Controls Framework to identify, prioritize, and measure our cybersecurity controls and defenses. Our information security program includes:
| Policies and routine security awareness training, |
| Identification and remediation of information security risks and vulnerabilities in our IT systems, including regular scanning of both internal and externally facing systems and annual third-party penetration testing, |
| Implementation of security technologies that are able to identify and assist in containing and remediating malware risks, |
| Active monitoring of logs and events for our network perimeter and internal systems, |
| Due diligence of information security programs for third-party vendors that handle sensitive data, and |
| Testing of incident response procedures. |
We also maintain a cyber insurance policy that provides coverage for security breach recovery and response.
Risk and Compensation
The OCC regularly reviews and assesses the possible risks related to our compensation programs. Based on this assessment, the OCC has concluded that the structure of our compensation programs does not create unreasonable risk or the likelihood of a material adverse impact on the Company.
In making this determination, the OCC considered possible compensation-based risks and means by which potential risks may be mitigated, including the operation of our internal control structure and the Committees oversight. The OCC also considered the structure of our compensation programs, including:
| Oversight of executive compensation by an independent committee of the Board. |
Page | 11
| Use of an independent compensation consultant. |
| The use of a combination of short- and long-term compensation programs to create a balanced mix of pay components for our executives. |
| Capped bonus targets for annual incentives and equity grant guidelines to govern the size of grants. |
| Equity ownership guidelines for our senior executives to strengthen the connection between executive and stockholder interests. |
| A robust compensation recovery (clawback) policy to reduce the risk that executives would be motivated to maximize performance in a specific period over long-term goals. |
| Double-trigger change-in-control provisions in agreements with our Named Executive Officers to prevent guaranteed payouts (see Potential Payments on Termination on page 47). |
Management Succession Planning
At least annually, and more often as deemed appropriate, the OCC meets with management to discuss succession plans for our executive management, including our Chief Executive Officer. Succession plans are designed to allow for an orderly transition of top executive posts either in the ordinary course of business or in response to emergency situations. Management develops and presents plans for identification, mentoring, and continuing development of potential internal candidates for executive leadership positions. The Committee provides oversight, input, and recommendations with regard to the criteria to be used for identification of potential candidates for succession to leadership positions. The Committee also meets with individual members of management occasionally throughout the year to assess leadership development within the executive team.
Related Party Transactions
We review all relationships and transactions in which the Company and our directors and executive officers or their immediate family members are participants. The Companys legal and governance staff is primarily responsible for monitoring and obtaining information from the directors and executive officers with respect to related party transactions and for then determining, based on the facts and circumstances, whether the Company or a related party has a direct or indirect material interest in the transaction.
Management reports related party transactions to the CGNC and Audit Committee in accordance with written policy and the CGNC and Audit Committee review and approve (or ratify) all transactions between the Company and related parties that are required to be disclosed under SEC rules.
Under this policy, the Committee has deemed certain transactions to be pre-approved or ratified even if the aggregate amount involved exceeds thresholds that would otherwise require disclosure as follows:
| Compensation paid for service as a non-employee director or executive officer of the Company, |
| Transactions with other companies where the related partys only relationship is as a director and/or beneficial owner of less than 10% of that companys equity interests, |
| Transactions where the related partys only interest arises from the ownership of the Companys common stock and all holders of the Companys common stock received the same benefit on a pro rata basis (such as payment of regular dividends or stock splits), |
| Transactions between parent and subsidiary entities within the Companys subsidiary structure, joint ventures, equity investments, and limited liability entities, |
| Transactions where law or government authority regulate the rates or charges, and |
| Transactions involving services as a bank depositary of funds, transfer agent, registrar, trustee under a trust indenture, or similar services. |
Page | 12
KPMG, as our independent registered public accounting firm, reviews our controls around the identification and reporting of related party transactions as required by current accounting and auditing standards.
We have determined that there were no material related party transactions during the 2022 fiscal year.
The Audit Committee operates under a written charter which can be found on our website at http://investor.coopercos.com/corporate-governance. The Audit Committee regularly reviews its charter to ensure that it is meeting all relevant policy requirements of the SEC, the Public Company Accounting Oversight Board, and the NYSE.
The Audit Committee assists the Board in fulfilling its oversight responsibilities regarding: (i) the quality and integrity of the Companys financial statements, (ii) the Companys compliance with legal and regulatory requirements, (iii) review of our potential risk factors, (iv) our system of internal accounting and financial controls, (v) our enterprise risk management program, (vi) the qualifications and independence of the independent registered public accounting firm (the Independent Auditors) and (vii) the oversight and performance of the Companys internal audit function and the Independent Auditors.
The Audit Committee had four members for the majority of fiscal 2022, with a fifth member added in October 2022. Our Board has determined that all five members of the Audit Committee are independent directors as required by the SEC and NYSE and are financially literate as required by the NYSE. The Board has further determined that Ms. Lindell, Ms. Lucchese, and Ms. Madden each meet the qualifications of an audit committee financial expert as defined by the SEC.
Independent Auditors and Internal Controls
The Audit Committee is directly responsible for the appointment, compensation, retention, and termination of our Independent Auditors for the purpose of preparing or issuing an audit report or related work or performing other audit, review, or attest services for the Company.
Oversight of the work of our Independent Auditors includes:
| Review and approval of the planned scope of our annual audit. |
| Review of their continued independence. |
| Review and pre-approval of any audit and non-audit services that may be performed by our Independent Auditors. |
| Review of the adequacy of our internal financial and disclosure controls with management and our Independent Auditors. |
| Review of our critical accounting policies and the application of accounting principles. |
| Reviewing the auditors report and critical audit matters presented by the Independent Auditors. |
| Monitoring the Independent Auditors rotation of partners on our audit engagement team as required by regulation. |
The Independent Auditors report directly to the Audit Committee.
Page | 13
The Company has a full-time internal audit function that reports to the Audit Committee and the Chief Financial Officer, and is responsible for, among other things, objectively reviewing and evaluating the adequacy, effectiveness, and quality of the Companys system of internal controls. To support this work, management has engaged Ernst & Young LLP to assist the Companys internal audit team. The Audit Committee is responsible for oversight and performance of the Companys internal audit function
KPMG serves as our Independent Auditors and is responsible for performing an independent audit of the Companys consolidated financial statements, as well as our internal controls over financial reporting, in accordance with the standards of the Public Company Accounting Oversight Board (United States). The Audit Committees responsibility is to monitor and oversee these processes. In this context, the Audit Committee has met and held discussions with management and KPMG regarding the fair and complete presentation of the Companys financial results.
The Audit Committee reviews the independence and quality control procedures of KPMG and the experience and qualifications of KPMG senior personnel that are providing audit services to the Company at least annually. In conducting its review of KPMG, the Audit Committee considers:
| Historical and recent performance, including the results of an internal survey of KPMGs service. |
| Quality and professional reputation, utilizing the questionnaire published by the Center for Audit Quality. |
| External data relating to audit quality and performance, including recent Public Company Accounting Oversight Board (PCAOB) reports on KPMG and its peer firms. |
| The value of KPMGs services in light of the fees charged to the Company. |
| KPMGs tenure as our Independent Auditors and its familiarity with our global operations and businesses, accounting policies and practices and internal control over financial reporting. |
| KPMGs capability and expertise in handling the breadth and complexity of our worldwide operations. |
| KPMGs compliance with the partner rotation requirements established by the SEC. |
| KPMGs integrity and objectivity. |
| KPMGs independence from the Company consistent with PCAOB Rules, and the impact that any relationships or services may have on the objectivity and independence. |
Based on this evaluation, including the factors discussed above, the Audit Committee has concluded that KPMG is independent and believes it is in the best interests of the Company and its stockholders to retain KPMG to serve as our Independent Auditors.
The Audit Committee has also set clear hiring policies regarding the Companys hiring of present or former employees of KPMG.
Procedures for Handling Accounting Complaints
The Audit Committee has established procedures for receipt and handling of potential complaints we may receive regarding accounting, internal accounting controls, or auditing matters, and to allow for the confidential, anonymous submission by our employees of concerns regarding accounting or auditing matters. In furtherance of this goal, we have established a confidential reporting system managed by an independent third-party vendor through which employees may report concerns about our business practices. The reporting system provides both a telephone hotline and online reporting options in multiple languages.
Page | 14
Fees Paid to KPMG LLP
The Audit Committee or its Chair approved all audit services provided by KPMG for the fiscal year ended October 31, 2022 prior to the work being performed. The total fees paid or payable to KPMG for the last two fiscal years are as follows:
Fiscal Year Ended | ||||
|
October 31, 2022 | October 31, 2021 | ||
Audit Fees |
$5,290,720 | $4,552,450 | ||
Audit Related Fees |
$-0- | $-0- | ||
Tax Fees |
$20,000 | $6,000 | ||
All Other Fees |
$5,000 | $-0- |
| Audit Fees include the audit of the Companys annual financial statements, review of financial statements included in each of our Quarterly Reports on Form 10-Q and services that are normally provided by KPMG in connection with statutory and regulatory filings or engagements for those fiscal years. This category also includes audit related work over acquisitions and our ongoing adoption of new accounting standards. |
| Audit-Related Fees consist of fees for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements. |
| Tax Fees consist of fees for professional services for tax compliance and consulting. This category includes fees primarily related to the preparation and review of federal, state, and international tax returns and assistance with tax audits. |
| All Other Fees include assurance services not related to the audit or review of our financial statements. |
Our Audit Committee determined that the rendering of non-audit services by KPMG is compatible with maintaining the independence of KPMG.
Audit Committee Pre-Approval Procedures
The Audit Committee maintains policies and procedures for the pre-approval of work performed by KPMG. Under its charter, the Audit Committee must approve all engagements in advance. All engagements with estimated fees above $150,000 require consideration and approval by the full Audit Committee. The Chair of the Audit Committee has the authority to approve on behalf of the full Audit Committee all engagements with fees estimated to be below $150,000, and any such approvals are reported to the Audit Committee at a subsequent meeting. Management recommendations are considered in connection with such engagements, but management has no authority to approve engagements.
Page | 15
The information contained in this report shall not be deemed filed with the SEC and is not incorporated by reference into any filing by Cooper under the Exchange Act.
During fiscal year 2022, the Audit Committee reviewed and discussed with management the processes and procedures associated with our assessment of internal controls over financial reporting, including managements assessment of the effectiveness of such controls.
The Audit Committee also reviewed the quality and integrity of the Companys consolidated financial statements, its compliance with legal and regulatory requirements, the qualifications and independence of its independent registered public accounting firm, the performance of KPMG, and other significant financial matters.
The Audit Committee met seven times, including telephone meetings, during the 2022 fiscal year.
The Audit Committee reviewed and discussed the audited consolidated financial statements of the Company for the fiscal year ended October 31, 2022 with management and KPMG, and management represented to the Audit Committee that our consolidated financial statements were prepared in accordance with United States generally accepted accounting principles (GAAP).
The Audit Committee discussed with KPMG the matters required to be discussed by the Public Company Accounting Oversight Board Auditing Standard No. 1301 Communication with Audit Committees and received both the written disclosures and the letter from KPMG that are mandated by applicable requirements regarding the independent registered public accounting firms communications with the Audit Committee concerning independence and the Audit Committee discussed KPMGs independence from the Company with the lead engagement partner.
Based on the review and discussions noted above, the Audit Committee recommended to the Board that the Companys audited consolidated financial statements be included in its Annual Report on Form 10-K for the fiscal year ended October 31, 2022 and be filed with the SEC.
THE AUDIT COMMITTEE
Teresa S. Madden (Chair)
Jody S. Lindell
Cynthia L. Lucchese
Gary S. Petersmeyer
Maria Rivas, M.D.
Page | 16
Principal Securityholders
The following table contains information regarding all individuals or groups who have advised us that they own more than five percent (5%) of the outstanding shares of our common stock. Information is presented as of the Record Date and reflects information reported on the most recently filed Schedule 13G for each of the listed securityholders.
Name & Address of Beneficial Owner | Aggregate # of Shares Beneficially Held |
Percentage of Shares | ||
The Vanguard Group, Inc. (1) |
5,298,087 | 10.720% | ||
BlackRock, Inc. (2) |
4,000,869 | 8.100% | ||
T. Rowe Price Associates, Inc. (3) |
3,159,263 | 6.300% | ||
|
(1) | Based on information disclosed in a Schedule 13G/A filed by The Vanguard Group, Inc. on February 9, 2022 regarding ownership as of December 31, 2021. The Vanguard Group beneficially owns and has the sole power to dispose of or direct the disposition of 5,100,843 of these shares and has the shared power to dispose of or direct the disposition of 197,244 of these shares and has the shared power to vote 77,209 of these shares. |
(2) | Based on information disclosed in a Schedule 13G/A filed by BlackRock, Inc. on February 1, 2022 regarding ownership as of December 31, 2021. BlackRock, Inc., directly and through its subsidiaries, beneficially owns, and has the sole power to dispose of or direct the disposition of all 4,000,869 of these shares and has the sole power to vote or direct the vote of 3,489,511 of these shares. |
(3) | Based on information disclosed in a Schedule 13G/A filed by T. Rowe Price Associates, Inc. on February 14, 2022 regarding ownership as of December 31, 2021. T. Rowe Price Associates beneficially owns and has the sole power to dispose of or direct the disposition of all 3,159,263 of these shares and has the sole power to vote or to direct the vote of 1,192,528 of these shares. |
Securities Held by Insiders
The following table contains information regarding ownership of our common stock by each of our directors, the executives named in the Summary Compensation Table, and all of the current directors and executive officers as a group. The figures in this table represent sole voting and investment power except where otherwise indicated.
|
Common Stock Beneficially Owned as of January 19, 2023 | |||||
Name of Beneficial Owner | Number of Shares |
Percentage of Shares | ||||
Brian G. Andrews (1) |
52,758 | * | ||||
Colleen E. Jay (2) |
7,113 | * | ||||
William A. Kozy (3) |
7,418 | * |
Page | 17
|
Common Stock Beneficially Owned as of January 19, 2023 | |||||
Name of Beneficial Owner | Number of Shares |
Percentage of Shares | ||||
Jody S. Lindell (4) |
27,884 | * | ||||
Cynthia L. Lucchese |
- | |||||
Teresa S. Madden |
1,056 | * | ||||
Daniel G. McBride (5) |
157,359 | * | ||||
Gary S. Petersmeyer (6) |
4,816 | * | ||||
Maria Rivas, M.D. |
502 | * | ||||
Holly R. Sheffield (7) |
50,542 | * | ||||
Gerard H. Warner III (8) |
9,753 | * | ||||
Robert S. Weiss (9) |
321,042 | * | ||||
Albert G. White III (10) |
308,371 | * | ||||
All current directors and executive officers as a group (15 persons) |
967,086 | 2.0% |
* | Less than 1% ownership. |
(1) | Includes 49,251 shares which Mr. Andrews could acquire upon the exercise of currently exercisable stock options. |
(2) | Includes 1,766 shares which Ms. Jay could acquire upon the exercise of currently exercisable stock options. |
(3) | Includes 1,766 shares which Mr. Kozy could acquire upon the exercise of currently exercisable stock options. |
(4) | Includes 8,091 shares which Ms. Lindell could acquire upon the exercise of currently available stock options; all of Ms. Lindells exercisable options are held by estate planning trusts in which Ms. Lindell maintains 50% or greater control. |
(5) | Includes 123,055 shares which Mr. McBride could acquire upon the exercise of currently exercisable stock options. |
(6) | Includes 1,782 shares which Mr. Petersmeyer could acquire upon the exercise of currently available stock options; all of these exercisable options are held by an estate planning trust in which Mr. Petersmeyer maintains 50% or greater control. |
(7) | Includes 45,280 shares which Ms. Sheffield could acquire upon the exercise of currently exercisable stock options. |
(8) | Includes 7,247 shares which Mr. Warner could acquire upon the exercise of currently exercisable stock options. |
(9) | Includes 177,202 shares which Mr. Weiss could acquire upon the exercise of currently exercisable stock options. |
(10) | Includes 266,941 shares which Mr. White could acquire upon the exercise of currently exercisable stock options. |
Page | 18
EXECUTIVE OFFICERS OF THE COMPANY
Set forth below is information regarding our executive officers (other than our CEO, who is also a director) as of February 1, 2023.
DANIEL G. MCBRIDE |
Age: 58 | |
Executive Vice President & Chief Operating Officer |
Mr. McBride has served as Executive Vice President and Chief Operating Officer since November 2013. He also served as interim General Counsel and Secretary from March 2022 through July 2022. He previously served as President of CooperVision, our contact lens business, from February 2014 through February 2022, as our Chief Risk Officer from July 2011 through October 2013, as our General Counsel from November 2007 through January 2014, and as Vice President from July 2006 through October 2013. He served as Senior Counsel from February 2005 through November 2007. Prior to joining Cooper, Mr. McBride was an attorney with Latham & Watkins LLP from October 1998 to February 2005, concentrating on mergers and acquisitions and corporate finance matters. He holds a B.S. in Finance from Santa Clara University and a J.D. from Stanford Law School.
BRIAN G. ANDREWS |
Age: 44 | |
Executive Vice President, Chief Financial Officer & Treasurer |
Mr. Andrews has served as Executive Vice President, Chief Financial Officer & Treasurer since December 2020. He previously served as our Senior Vice President, Chief Financial Officer & Treasurer from May 2018, and as Treasurer since January 2013 and Vice President since November 2014. He also served as Vice President, Global Logistics and Service for CooperSurgical, a position he held from June 2017 to May 2018. Mr. Andrews previously served as Assistant Treasurer for the Company from April 2006 to December 2012. Prior to joining Cooper, he held various corporate and investment banking positions at KeyBanc Capital Markets from 2002 to 2006 and at ING Barings from 2000 to 2001. He holds a B.A. in Economics from Columbia University.
HOLLY R. SHEFFIELD |
Age: 52 | |
President, CooperSurgical, Inc. |
Ms. Sheffield has served as President of CooperSurgical, Inc., our womens healthcare business, since July 2020. Previously, she served as Executive Vice President & Chief Strategy Officer from June 2018 to July 2020. Prior to joining Cooper, Ms. Sheffield had over 20 years of experience in investment banking. She joined Cooper from UBS Securities LLC, where she was a Managing Director, Global Head of Medical Technology from 2009 to May 2018. From 2000 to 2009, Ms. Sheffield was at Credit Suisse and from 1997 to 2000, Ms. Sheffield was at Donaldson, Lufkin & Jenrette until Credit Suisse acquired the firm. Ms. Sheffield currently serves on the board of Imperative Care, Inc., a private medical device company, and serves on the audit committee. She received a B.S. from Cornell University and an M.B.A. from Columbia Business School.
Page | 19
GERARD H. WARNER III |
Age: 58 | |
President, CooperVision, Inc. |
Mr. Warner has served as President, CooperVision, Inc. from February 2022. He previously served as Executive Vice President, Americas & Global Commercial Functions of CooperVision from April 2019 to January 2022 and as President, Americas from May 2015 to March 2019. Mr. Warner served in various other Vice President and Senior Vice President positions with CooperVision from May 2012 through April 2015. Prior to joining CooperVision, Mr. Warner spent 17 years at Bausch + Lomb in a variety of marketing and management roles. Mr. Warner earned a B.S. in Business Administration in Marketing from Villanova University and an M.B.A. from The Simon School of Business, University of Rochester.
NICHOLAS S. KHADDER |
Age: 49 | |
Vice President, General Counsel & Secretary |
Mr. Khadder has served as Vice President, General Counsel & Secretary since August 2022. He previously served as general counsel of Standard BioTools, Inc. (formerly Fluidigm Corporation) from June 2016 to July 2022. From 2010 to June 2016, he held various positions at Amyris, Inc., including general counsel and corporate secretary from 2013 to June 2016. Previously, he served in senior corporate counsel roles at LeapFrog Enterprises, Inc. from August 2008 to September 2010, and at Protiviti Inc. (a subsidiary of Robert Half International Inc.) from June 2005 to July 2008. Mr. Khadder started his legal career as a corporate attorney at Fenwick & West LLP from October 1998 to May 2005. He holds an A.B. in English from the University of California, Berkeley and a J.D. from the University of California, Berkeley, School of Law.
AGOSTINO RICUPATI |
Age: 56 | |
Senior Vice President, Finance & Tax / Chief Accounting Officer |
Mr. Ricupati has served as our Chief Accounting Officer since October 2017 and as Senior Vice President, Finance & Tax since July 2017. Mr. Ricupati previously served as Vice President, Tax for the Company from July 2013 to July 2017. Prior to joining Cooper, he served as International Tax Director for Intel Corp. from 2010 to 2013 and in various other senior finance and tax positions over the past 20 years. He holds a masters degree from DePaul University and is a Certified Public Accountant.
Page | 20
COMPENSATION DISCUSSION AND ANALYSIS
COMPENSATION DISCUSSION AND ANALYSIS |
||||
22 | ||||
24 | ||||
26 | ||||
26 | ||||
27 | ||||
28 | ||||
28 | ||||
29 | ||||
29 | ||||
30 | ||||
31 | ||||
31 | ||||
36 | ||||
38 | ||||
39 | ||||
39 | ||||
40 |
This Compensation Discussion and Analysis describes our compensation program and the compensation decisions made by the OCC related to the compensation of our Chief Executive Officer, Chief Financial Officer, and our three other most highly compensated executive officers serving as of October 31, 2022 (collectively, our named executive officers, or NEOs) in the following roles:
Name |
Title | |
Albert G. White III |
President & Chief Executive Officer | |
Brian G. Andrews |
Executive Vice President, Chief Financial Officer & Treasurer | |
Daniel G. McBride |
Executive Vice President & Chief Operating Officer | |
Holly R. Sheffield |
President, CooperSurgical, Inc. | |
Gerard H. Warner III |
President, CooperVision, Inc. | |
Page | 21
Fiscal 2022 Performance - The Year in Review
Fiscal 2022 was a strong year for CooperCompanies, with record revenues of $3.31 billion. Both our CooperVision and CooperSurgical businesses posted record revenues, and CooperSurgical exceeded $1 billion in revenue for the first time, supported by our acquisition of Generate Life Sciences. These results included CooperVision finishing the year posting its seventh consecutive quarter of double-digit organic revenue growth and CooperSurgical posting its eighth consecutive quarter of double-digit organic revenue growth for its fertility business. This was accomplished in a very difficult business environment with substantial supply chain challenges from ongoing COVID-19 constraints and the war in Ukraine, in conjunction with global inflationary pressures. Additionally, given our significant international operations, foreign currency had a notable negative impact on our as-reported results, especially our non-GAAP EPS.
Despite notable headwinds from foreign currency, inflation, and supply chain pressures, we maintained our strategic focus on long-term sustainable revenue growth and market share gains with targeted investments, including within our silicone hydrogel family of contact lenses, and our specialty contact lens and fertility businesses. Furthermore, we closed the largest acquisition in our history, made several important leadership enhancements, launched several new products, and improved our ESG efforts, including starting the operation of our new power plant in Puerto Rico, which will provide significant environmental benefits.
2022 Financial Highlights
| ||||||||
Budget Target | FY2022 Results (Constant Currency) (1) |
FY2022 Results | Change YoY | |||||
Revenue: |
$3.40 billion | $3.49 billion | $3.31 billion |
![]() | ||||
CooperVision: |
$2.32 billion | $2.39 billion | $2.24 billion |
![]() | ||||
CooperSurgical: |
$1.08 billion | $1.1 billion | $1.07 billion |
![]() | ||||
Non-GAAP (2) EPS: |
$14.85 | $14.57 | $12.42 |
![]() | ||||
Stock Price (10/31/2022): |
$273.39 |
![]() | ||||||
(1) | Constant currency results used for consideration of achievement for annual cash incentive compensation. The impact of currency rates on our fiscal 2022 results is discussed in detail in the Consolidated Financial Statements and other disclosures included in our 2022 Annual Report. |
(2) | For a reconciliation between GAAP and non-GAAP measures, see the Reconciliation of Non-GAAP Financial Measures section of this Proxy Statement. |
In addition to record revenues and strong organic growth, we were able to make progress on multiple key initiatives during the 2022 fiscal year, including:
| CooperVision launched a new MyDay® multi-focal lens and expanded its MyDay® toric parameters, giving us the widest range of one-day toric contact lenses on the market. |
| CooperVision continued growing its specialty eye care business, including: |
○ | Entering into a joint venture to commercialize SightGlass myopia management spectacle lenses, expanding availability in Europe and entering the China market. |
Page | 22
○ | Launching MiSight® contact lenses in multiple new markets, including China, making the product available in 41 countries. |
○ | Expanding the parameter range offered for MiSight®, providing additional product options for customers. |
○ | Advancing multiple R&D efforts. |
○ | Partnering with numerous organizations to advance efforts around myopia control, including the World Council of Optometry, the International Myopia Institute, the International Association for the Prevention of Blindness, and others. |
| CooperSurgical completed the acquisition of Generate Life Sciences. This significant acquisition expanded our addressable fertility market into donor gamete (egg and sperm) and extended our obstetric reach into umbilical cord blood and tissue storage. |
| CooperSurgical also entered into an asset purchase agreement to acquire Cook Medicals Reproductive Health business. |
| CooperVision and CooperSurgical each progressed multiple infrastructure improvements, including: |
○ | Commenced operation of a new, autonomous power plant for our CooperVision facility in Puerto Rico, providing reliable, cost-effective power with significant, positive environmental attributes. |
○ | Continued expansion of our distribution and packaging facilities, including the implementation of substantial automation to support growing operations. |
○ | Expansion of manufacturing operations to increase production capacity and centralize operations. |
| We continued to raise capital to support strategic projects, including closing a new $1.5 billion term loan to fund the acquisition of Generate Life Sciences and an $840 million 364-day term loan to expand funding and reduce costs. |
| We have received recognition from multiple sources as a great place to work, including: |
○ | Recognized as a Top 50 Inspiring Workplace in North America by The Inspiring Workplaces Group. |
○ | Awarded Top Great Place to Work for Large Manufacturing companies for the third year in a row and achieved Top 50 Innovative Workplace recognition. |
○ | Identified as one of Fortunes Top 10 Best Large Workplaces in Manufacturing and Production for the second year in a row. |
○ | Certified as a Great Place to Work for the fourth consecutive year. |
○ | Achieved a score of 100% on the Human Rights Campaign Foundations Corporate Equality Index 2022. |
| We continued development of our ESG initiatives, as detailed in our ESG Report (which can be found on our website at https://www.coopercos.com/esg/). We encourage you to read the report for information regarding our ESG initiatives, including our continued efforts to reduce our reliance on fossil fuels and initiatives to reduce plastic waste. |
Overall, we are proud of our successes during the 2022 fiscal year and our momentum entering fiscal 2023. The OCC took these efforts, and the resulting achievements, into consideration in its executive compensation decisions for fiscal 2022.
Page | 23
Fiscal 2022 Compensation Highlights
Our executive compensation program is designed to support our business and compensation objectives and to reinforce our pay-for-performance culture. During fiscal 2022, we maintained our emphasis on performance-based compensation through achievement of financial goals in our 2022 Incentive Payment Plan (the 2022 IPP) and use of long-term equity awards, granted as a combination of performance-based equity awards, granted as performance shares, and time-vested stock options and/or restricted stock units (RSUs).
In fiscal 2022, approximately 91% of Mr. Whites target total direct compensation was tied to financial and stockholder return outcomes, including 50% of his equity awards being granted in the form of performance shares, which vest based on financial performance over a three-year period. Approximately 79% of our other NEOs target total direct compensation (on average) was tied to financial and stockholder return outcomes.
Page | 24
* All Other Compensation, as discussed in footnote 4 to the Summary Compensation Table on page 41, represents less than 1% of total target direct compensation for our NEOs, including Mr. White.
Fiscal 2022 Incentive Payment Plan Result
Payments under the 2022 IPP were determined based on achievement of a mix of quantitative financial metrics, representing 75% of the target bonus opportunity, and non-financial goals, representing 25% of the target bonus opportunity. This approach reflects a change from the IPP bonus in prior years, when 25% of the target bonus for NEOs was determined based on the OCCs discretionary evaluation of each NEOs individual performance (in addition to 75% tied to quantitative financial metrics, which weighting was unchanged for this year).
The quantitative financial metrics selected for the 2022 IPP were revenue, and operating income or non-GAAP EPS, all measured on a constant currency basis. Non-financial goals selected for the 2022 IPP included operational, organizational, and business goals not explicitly reflected in the quantitative financial metrics selected for the 2022 IPP. The non-financial goals for our NEOs were generally aligned with the objectives approved by the Board for Mr. White at the beginning of the fiscal year, and determination of NEO achievement was dependent on the OCCs assessment of executive performance against the designated goals.
The OCCs decision to measure performance against specific non-financial goals in the 2022 IPP was finalized following a detailed review of our executive compensation program during fiscal 2021. This review, completed with input from the OCCs independent compensation consultant, incorporated market perspective from our compensation peer group as well as an overall evaluation of our compensation philosophy and objectives. The OCCs decision to transition from a discretionary determination of achievement to an evaluation of specific non-financial goals reflects the OCCs objective of creating a more formal connection between annual performance-based cash incentive awards and key non-financial strategic objectives that are the foundation of long-term stockholder value creation.
On review of the fiscal 2022 financial results and assessment of achievement against the designated non-financial goals, the OCC certified overall achievement of between 114.5% to 142.7% of target for each of the NEOs. This included the OCCs determination that the NEOs had met or exceeded the objectives set for the non-financial goals, resulting in achievement at 140% of target for the portion of annual bonuses based on those measures.
This determination, including quantitative achievement, the approved non-financial goals, and considerations in setting NEO achievement, is discussed in more detail below, starting on page 31.
Page | 25
Consideration of 2022 Say-on-Pay Vote
The OCC considered the outcome of our annual Say-on-Pay vote in determining the design of our executive compensation program and the composition and levels of individual compensation packages for the 2022 fiscal year.
At our 2022 Annual Meeting approximately 91% of the votes cast on our Say-on-Pay proposal were voted in favor of the compensation program for our NEOs. The OCC viewed this an indication of support for our NEO compensation in fiscal 2021 and considered this result in setting compensation for fiscal 2022 as described in this Compensation Discussion and Analysis.
The OCC oversees our executive compensation program. In this capacity, the OCC regularly reviews our program to ensure that we maintain an effective and appropriate link between pay and performance and that our compensation practices do not encourage behaviors that could have adverse effects on the Company.
The OCC seeks to ensure we maintain sound governance and compensation policies and practices. In designing and overseeing our executive compensation program we strive to employ best practices, and the OCC works closely with its compensation consultant, management, and such other advisors as the OCC considers appropriate to properly assess our policies and practices.
THINGS WE DO: |
THINGS WE DONT DO: | |||
|
| |||
|
|
| ||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
Page | 26
THINGS WE DO: |
THINGS WE DONT DO: | |||
|
||||
|
||||
The OCC also regularly assesses the alignment between our executive compensation packages and our performance through:
| Regular updates from management on our business results, |
| Review of our quarterly financial statements, management projections, and long-range plans, |
| Review of management reports on continued progress on long-term strategies, |
| Review of performance and market information regarding our peer group, and |
| Review of broader industry compensation data relative to our market and other companies of comparable size. |
The OCC considers management input, the advice of its compensation consultant, and publicly available peer information to be valuable tools in evaluating the relationship between executive compensation and Company performance.
Compensation Objectives / Pay for Performance
Our executive compensation program is designed to provide market-competitive target total direct compensation opportunities for our NEOs based on a pay for performance philosophy and to align our NEOs interests with those of our stockholders by emphasizing certain principles:
| Aligning compensation with performance by connecting executive compensation to financial measures that correlate strongly with stockholder returns, |
| Balancing short-term financial results with long-term strategic objectives, |
| Rewarding achievement of challenging corporate objectives, without encouraging inappropriate risk-taking, |
| Providing competitive pay packages aligned to market compensation practices, and |
| Maintaining sufficient flexibility to allow recognition of significant individual achievements by our executive officers. |
The OCC believes that each element of executive compensation and the total compensation provided to each of our NEOs is reasonable, competitive, and appropriate. The OCC believes that our executive compensation program provides an appropriate mix of elements that will allow us to continue to attract, retain, and motivate a top-performing management team, without encouraging excessive or inappropriate risk-taking by our executive officers, and that our compensation arrangements create incentives that drive our continued strong financial performance.
Page | 27
The compensation payable to our NEOs depends primarily on our financial performance and returns to our stockholders. This strategy has created strong financial and operational results and we have maintained steady growth and returns for our stockholders over the past decade. We consider our executive compensation program design to be integral to our success and believe the performance measures selected for use in our incentive compensation plans serve as significant drivers of our continued success.
Compensation Recovery Policy
As part of the OCCs pay for performance philosophy, the OCC has adopted a policy for recovery of incentive-based compensation in the event of misconduct by our NEOs. Under the policy, in the event we are required to prepare an accounting restatement to correct an error that is material to previously issued financial statements, the Company may recover compensation granted or earned in connection with our incentive payment plans, equity compensation, or other incentive compensation plans in the three fiscal years prior to the recoverable event. The OCC administers the policy and it applies to all executive officers, including the NEOs.
Use of Compensation Consultants
In fiscal 2022, the OCC retained Compensia to provide information and analysis on the compensation of our executive officers and the non-employee members of our Board. The OCC maintains sole authority to determine the terms of Compensias retention and services, and a representative of Compensia generally attends OCC meetings.
The OCC has reviewed the nature of the relationship between itself and Compensia as an independent consulting firm, and its relationship with the members of Compensia as individuals, for potential conflicts of interest. In conducting this review, the OCC considered the factors identified by the SEC and the NYSE as possibly contributing to conflicts, including the scope of work performed for the OCC by Compensia, the fees paid to Compensia for services, and any personal or business relationships between our executive officers or members of the OCC and Compensia or its individual members. Based on its review, the OCC determined there were no conflicts of interest or potential conflicts of interest arising in connection with the OCCs engagement of Compensia.
The OCC considers input from management regarding executive compensation and performance to be a valuable tool in setting appropriate compensation levels. In addition to recommendations regarding annual executive compensation, management also provides recommendations to the OCC regarding:
| Selection of companies for our compensation peer group (as described further below), |
| Appropriate structure for our annual incentive payment plan, including financial performance measures, non-financial objectives, target performance levels, and calculation or determination of achievement levels, |
| Long-term incentive plan design and annual award allocations, |
| Employment terms and arrangements, and |
| Stock trading and incentive compensation recovery policies and ownership guidelines. |
The OCC reviews management recommendations with its compensation consultant before making its own decisions on the compensation of our NEOs.
Page | 28
The OCC uses a peer group for understanding and assessing competitive compensation levels and practices within our industry. Our compensation peer group is drawn from publicly-traded companies headquartered in the United States and is reviewed annually.
Recommendations for peer group companies are based on similarity of product lines or industry and similarity in company size as measured by annual revenue, market capitalization, operating margins, and other financial measures of organizational scope and complexity.
For fiscal 2022, companies in Healthcare Equipment, Healthcare Supplies, and Life Sciences Tools and Services industries with comparable business focuses and end markets (generally healthcare supplies or equipment and hospital or health-care provider end markets) were considered for inclusion in our compensation peer group. Our peer group selection criteria also targeted revenues between about $1.2 billion and $4.9 billion in the previous fiscal year (about 0.5x to 2.0x our own revenue) and market capitalizations between about $6.5 billion and $59 billion (about 0.3x to 3.0x our own market capitalization)
Our compensation peer group for fiscal 2022 comprised the following companies:
Agilent Technologies, Inc. | Illumina, Inc. | |
Align Technology, Inc. | Integra Lifesciences Holding Corporation | |
Bio-Rad Laboratories, Inc. | Masimo Corporation | |
Charles River Laboratories International, Inc. | PerkinElmer, Inc. | |
Dentsply Sirona, Inc. | ResMed, Inc. | |
DexCom, Inc. | Steris PLC | |
Edwards Lifesciences Corporation | Teleflex Incorporated | |
Hill-Rom Holdings. Inc. Hologic, Inc. |
Waters Corporation |
This group reflects updates from the peer group for fiscal 2021 as follows:
Removed
| Haemonetics Corporation - fell below target revenue and market capitalization criteria |
| Varian Medical Corporation acquired |
Added
| Charles River Laboratories International, Inc. relevant business match within financial criteria |
| Steris PLC relevant business match within financial criteria |
The OCCs goal is generally to set all elements of NEO compensation within a competitive range, using a balanced approach that does not use rigid percentiles to target pay levels for each compensation element. For fiscal 2022, the OCC reviewed each element of compensation described below and set the target total direct compensation opportunities of our executive officers after taking into consideration the following factors:
| A compensation analysis of competitive market data performed by Compensia, |
Page | 29
| Each executive officers scope of responsibilities, skill set, prior experience, and time in their position, |
| The recommendations of our Chief Executive Officer, and |
| General market conditions. |
The OCC does not assign relative weights or rankings to any of these factors and does not solely use any quantitative formula, target percentile, or multiple for establishing compensation among the executive officers or in relation to the competitive market data. Instead, the OCC relies upon its members knowledge and judgment in assessing the various qualitative and quantitative inputs it receives regarding each individual and makes compensation decisions accordingly.
The primary elements of our executive compensation program are designed to allow us to attract and retain qualified executive officers and to connect NEO compensation to stockholder returns and company objectives.
Base Salary |
Provides a minimum level of competitive compensation for our executives | |
Annual Cash Incentive |
Encourages achievement of short-term business goals as reflected in our annual operating budget | |
Long-Term Equity Incentives |
Connects equity incentives to strategic objectives and priorities linked to long-term success, supports alignment between executives and stockholders, and encourages executive retention |
The majority of NEO compensation is a combination of annual cash and long-term equity incentives. This creates a direct link between our performance and NEO compensation. Additionally, compensation is balanced between short-term and long-term factors to encourage attention to both annual financial and operational objectives and long-term strategic goals in order to drive long-term stockholder value creation.
Annual target total direct compensation for our NEOs is based on current role, recent changes to responsibilities, and overall execution of duties throughout the prior fiscal year. Company performance, internal compensation alignment, peer group practices, and competitive market changes and conditions are also considered.
Page | 30
We offer base salaries that are intended to provide a level of stable fixed compensation to our executive officers for performance of day-to-day services. Base salaries for our executive officers are generally reviewed annually to determine whether an adjustment is warranted or required, with any changes in base salary generally effective on the first day of our fiscal year.
Executive | 2021 Base Salary |
2022 Base Salary (1) |
% Change | |||
Albert G. White III |
$925,000 | $925,000 | No change | |||
Brian G. Andrews |
$500,000 | $550,000 | 10% | |||
Daniel G. McBride |
$700,000 | $725,060 | 3.6% | |||
Holly R. Sheffield |
$525,000 | $550,043 | 4.8% | |||
Gerard H. Warner III |
$375,950 | $450,000 | 19.7% | |||
(1) | Approved salaries for fiscal 2022 represent the salary approved by the OCC and may vary slightly from the reported salary actually paid to each NEO (as presented in the Summary Compensation Table on page 41) due to salary increases becoming effective on a calendar year basis. |
Salary changes for fiscal 2022 generally align to budgeted increases across the employee population, with the exception of changes to Messrs. Andrews and Warners salaries. The OCC has incrementally increased Mr. Andrews salary during his tenure as Chief Financial Officer to more closely align with compensation for this role within our peer group. This is consistent with the OCCs overall philosophy regarding retention of key talent and maintaining stable leadership for the Company.
Mr. Warner also received a more substantial increase in salary for fiscal 2022 in connection with his promotion to President of CooperVision. The promotion, which was announced in November 2021, took effect in February 2022, and the salary increase aligned Mr. Warners compensation with similar roles within the Company and our peer group.
Annual Cash Incentives 2022 Incentive Payment Plan
At the beginning of each fiscal year, the OCC approves an Incentive Payment Plan (IPP) to provide annual performance-based cash incentive opportunities. The OCC sets participation levels under the IPP (target incentive opportunities) for our NEOs.
Each NEOs annual incentive opportunity under the IPP is allocated into two components:
| 75% of the target is tied to quantitative, pre-established financial performance metrics, and |
| 25% of the target is payable based on specified non-financial goals intended to recognize strategic, operational, and individual accomplishments. |
This combination of financial metrics and non-financial goals encourages our executive officers, including our NEOs, to focus on both our immediate business objectives and short-term financial performance, as well as other non-financial factors that support longer-term performance.
Page | 31
Achievement levels for the quantitative financial performance metrics used in the IPP are based on targets in our annual operating budget, and achievement against the non-financial goals is based on the OCCs assessment of individual performance by the NEOs.
Target incentive opportunities under the IPP are calculated as a designated percentage of base salary for the fiscal year, and that percentage controls the potential award that can be achieved under the IPP as follows:
Total Bonus Paid ($) |
= | Base Salary ($) |
X | IPP Participation (%) |
X | Financial Metric and Non-Financial Goal Achievement (%) |
Quantitative Financial Performance Component
Quantitative financial performance measures and related target levels for the 2022 IPP were based on our annual operating budget, as approved by our Board at the beginning of fiscal 2022. Achievement for Messrs. White and Andrews was based on overall Revenue and non-GAAP EPS, adjusted for currency fluctuations. Achievement for Mr. Warner and Ms. Sheffield was based on revenue and operating income, adjusted for currency fluctuations, for each of CooperVision and CooperSurgical, respectively. Achievement for Mr. McBride was based 50% on overall revenue and non-GAAP EPS and 50% on Revenue and Operating Income, adjusted for currency fluctuations, of CooperVision. The weighting of these financial metrics is described below under Financial Objective Achievement.
The table below describes the relationship between how an award would be earned based on Company performance for each of the financial performance measures included in the 2022 IPP. No award would be payable with respect to any financial performance measure that did not reach its minimum achievement threshold. The maximum award for each NEO with regard to any individual financial performance measure was capped at 200%.
IPP Achievement Required to Attain Payout (1) | ||||||
Performance Measure | Threshold | Target | Maximum | |||
Revenue (Constant Currency) |
95% | 100% | 105% | |||
Non-GAAP EPS (Constant Currency) |
90% | 100% | 110% | |||
Operating Income |
90% | 100% | 110% | |||
(1) | Potential payments at each of Threshold, Target and Maximum are presented in the Grants of Plan Based Awards Table on page 42. Target achievement provides for payout of 100% of target bonus amounts and maximum achievement is capped at 200% of the target bonus amount. |
Adjustments to Quantitative Financial Metrics and Achievement
The 2022 IPP provides for adjustment to quantitative financial performance metrics for acquisitions and/or divestitures and other items during the fiscal year as determined by the Board. In making such adjustments, the OCC considers a report provided by management on variances to the budget goals for Revenue, Operating
Page | 32
Income, and non-GAAP EPS that highlights key variances including non-recurring, non-controllable, and/or discretionary items. The OCC may elect to include or exclude certain of these items for purposes of determining the achievement against the financial metrics.
The OCC has discretionary authority to reduce, by up to 25%, the amount awarded based the financial metric component of the annual cash incentive, regardless of achievement levels, to the extent the OCC considers such reduction to be in the Companys best interests based on any facts and circumstances. Award payments could also be reduced or wholly eliminated by the OCC if a review of the results for the first two months of fiscal 2023 reflected anomalous unfavorable events that were attributable to fiscal 2022.
Non-Financial Performance Component
Non-financial goals for the 2022 IPP were selected by the OCC at the beginning of fiscal 2022 to reflect operational, organizational, and business goals not directly reflected in the quantitative financial measures for the year. Achievement against the designated non-financial goals depended on the OCCs assessment of individual performance by the NEOs against the agreed objectives, subject to a cap on maximum achievement at 200%.
In determining achievement for the NEOs, the OCC considered Mr. Whites assessment of each NEOs performance against the selected objectives as well as the OCCs own evaluation of such performance and recommendations from Compensia.
Overall 2022 IPP Achievement
Based on the OCCs determination of achievement against the selected quantitative metrics and non-financial goals for fiscal 2022, the OCC approved the following awards for each NEO under the 2022 IPP.
Named Officer |
Participation Level | Financial Metrics | Non-Financial Goals | Award Payout (1) | ||||||||||||||
($) |
(% of Base Salary) |
Achievement | Goal Weighting |
Achievement |
Goal Weighting |
($) | (% of Target) |
(% of Base Salary) | ||||||||||
A. White |
$1,156,250 | 125% | 131.6% | 75% | 140% | 25% | $1,544,750 | 133.6% | 167.0% | |||||||||
B. Andrews |
$385,000 | 70% | 131.6% | 75% | 140% | 25% | $506,567 | 133.6% | 93.5% | |||||||||
D. McBride |
$580,048 | 80% | 137.6% | 75% | 140% | 25% | $796,435 | 138.1% | 110.5% | |||||||||
H. Sheffield |
$412,532 | 75% | 106.0% | 75% | 140% | 25% | $468,755 | 114.5% | 85.9% | |||||||||
G. Warner |
$292,500 | 65% | 143.6% | 75% | 140% | 25% | $391,595 | 142.7% | 89.5% |
(1) | Mr. McBrides achievement reflects weighting based on CooperVision performance due to his role as President, CooperVision prior to Mr. Warners promotion and Mr. Warners achievement reflects weighting for his prior role and his service as President, CooperVision. |
Page | 33
Achievement levels and awards paid reflect amounts approved based on the performance detailed below.
Financial Objective Achievement
Financial objective achievement under the 2022 IPP was determined by division as follows:
Overall
(Basis of financial objective achievement for Messrs. White and Andrews and 50% of achievement for Mr. McBride.)
Financial Metric (Constant Currency) |
Budget Target ($ in Millions; |
Metric Weighting |
Achievement ($ in Millions; except EPS) (% of Target) |
Weighted 2022 IPP (% of Target) |
||||||||||||
Revenue (1) |
$3,398.30 | 50% | $3,486.4 (102.6%) | 75.9% (151.8%) | ||||||||||||
Non-GAAP EPS (2) |
$14.85 | 25% | $14.57 (98.2%) | 22.7% (90.8%) | ||||||||||||
Total Achievement: |
75 | % | 98.6% (131.6%) |
(1) | Revenue as reported was $3,308.4 million versus 2022 IPP achievement of $3,486.4 million. The difference is due to adjustment to the foreign exchange rate used in connection with our annual budget. The foreign exchange rate used to compute the budget target was the same rate used for the 2022 IPP achievement calculation. |
(2) | Non-GAAP EPS as reported to investors was $12.42 versus 2022 IPP achievement of $14.57. The difference is due to adjustment to the foreign exchange rate used in connection with our annual budget. |
CooperVision
(Basis of financial objective achievement for Mr. Warner and 50% of basis for Mr. McBride.)
Financial Metric (Constant Currency) |
Budget Target ($ in Millions) |
Metric Weighting |
Achievement ($ in Millions) (% of Target) |
Weighted Achievement Under 2022 IPP (% of Target) |
||||||||||||
Revenue (1) |
$ | 2,319.7 | 50 | % | $2,389.5 (103%) | 80.1% (160.2%) | ||||||||||
Operating Income |
$ | 650.0 | 25 | % | $656.7 (101%) | 27.6% (110.3%) | ||||||||||
Total Achievement: |
75 | % | 107.7% (143.6%) |
(1) | Revenue for CooperVision as reported was $2,243.3 million versus 2022 IPP achievement of $2,389.5 million. The difference is due to adjustment to the foreign exchange rate used in connection with our annual budget and adjustment for acquisitions in the 2022 fiscal year. The foreign exchange rate used to compute the budget target was the same rate used for the 2022 IPP achievement calculation. |
CooperSurgical
(Basis of financial objective achievement for Ms. Sheffield.)
Financial Metric (Constant Currency) |
Budget Target ($ in Millions) |
Metric Weighting |
Achievement ($ in Millions) (% of Target) |
Weighted 2022 IPP (% of Target) |
||||||||||||
Revenue (1) |
$ | 1,078.6 | 50 | % | $1,096.8 (101.7%) | 66.9% (133.8%) | ||||||||||
Operating Income |
$ | 305.5 | 25 | % | $275.3 (90.1%) | 12.6% (50.5%) | ||||||||||
Total Achievement: |
75 | % | 79.5% (106.0%) |
(1) | Revenue for CooperSurgical as reported was $1,065.1 million versus 2022 IPP achievement of $1,078.6 million. The difference is due to adjustment to the foreign exchange rate used in connection with our annual budget and adjustment for acquisitions in the 2022 fiscal year. The foreign exchange rate used to compute the budget target was the same rate used for the 2022 IPP achievement calculation. |
Page | 34
A full discussion of our financial results can be found in Item 7, Managements Discussion and Analysis of Financial Condition and Results of Operations of our 2022 Annual Report. For a reconciliation between reported GAAP and non-GAAP measures, see the Reconciliation of Non-GAAP Financial Measures on page 83.
Non-Financial Objective Achievement
The non-financial goals selected by the OCC in December 2021 for fiscal 2022 were:
Category | Goals | |
Operational |
Advance our global myopia management portfolio (CooperVision) Drive growth and market share for our 1-day silicone hydrogel portfolio (CooperVision) Ensure success within our fertility business (CooperSurgical) Continue to address long-term effects of the COVID-19 pandemic Raise additional capital to support business activities | |
Organizational |
Ensure an effective and scalable organizational structure Support global organizational initiatives to remain an employer of choice | |
Business |
Execute successful M&A strategies Increase investor relations activities Advance ESG efforts both internally and externally |
On review of performance for the year, the OCC determined that the NEOs had met or exceeded the non-financial goals and set achievement at 140% of target for the 25% of each NEOs target incentive opportunity based on such goals. The OCCs determination was based on its own assessment of the NEOs accomplishments rather than a formulaic determination of achievement.
In making its determination, the OCC considered the following achievements against the selected objectives during the 2022 fiscal year.
Goals | Key Achievements | |
Myopia Management Portfolio |
Annual revenue of $93 million, up 45% organically over prior fiscal year Launched MiSight® contact lenses myopia correction in additional countries, including China Expanded available
MiSight® parameter range | |
1-Day Silicone Hydrogel Portfolio |
Record revenues with growth of 24%, driving daily market share to 20% Launched MyDay® multi-focal contact lenses and expanded MyDay® toric availability Launched the clariti® contact lens product in Japan | |
Fertility Business |
Record revenues of $431.6 million, up 35% (in constant currency) over prior fiscal year, driven by organic growth and acquisitions Continued to expand globally, grow market share, and launch new products | |
COVID-19 Pandemic Impacts |
Strongly supported employees, proactively managed global disruptions (including numerous logistics challenges) and delivered strong financial results, while advancing strategic initiatives including expanding, and upgrading, internal infrastructure |
Page | 35
Goals | Key Achievements | |
Raise Additional Capital |
Closed a new $1.5 billion term loan to fund the acquisition of Generate Life Sciences and an $840 million 364-day term loan to expand funding and reduce costs | |
Organizational Development / Employer of Choice |
Recognized as a Top 50 Inspiring Workplace in North America by The Inspiring Workplaces Group Awarded Top Great Place to Work for Large Manufacturing companies for the third year in a row and achieved Top 50 Innovative Workplace recognition Upgraded talent recognition and leadership development programs Expanded employee resource groups (ERGs), launching a Mental Health & Wellness ERG | |
Execute M&A Strategies |
Closed acquisition of Generate Life Sciences, the largest acquisition in the companys history Entered into asset purchase agreement to acquire Cook Medicals reproductive health business Entered into joint venture to commercialize myopia management spectacle lenses Closed several other strategic acquisitions and investments | |
Increase IR Activities |
Increased participation in conferences and roadshows, both in-person and virtually Increased proactive out-reach for follow-up calls following earnings announcements | |
Advance ESG Efforts |
Published second ESG Highlights Report with focus on improved data reporting Started operation of new power plant in Puerto Rico with significant environmental benefits Expanded plastic neutral program to 28 countries and expanded plastic neutral contact lens commitment to MyDay® products Completed Zero Waste to Landfill baseline assessment and waste stream. Increased number of LEED/BREEAM certified facilities globally |
Long-Term Incentive Compensation
For fiscal 2022, the OCC used a combination of time-vested and performance-based equity awards to deliver long-term incentive compensation to our NEOs. In setting equity compensation for our executive officers, the OCC discusses appropriate award design with Compensia and management to drive long-term focus on strategic objectives. The OCC also reviews historical grant levels based on the role and position of each executive officer, as well as economic and accounting implications, when determining the type and appropriate size of individual awards.
In setting award levels, the OCC considered market practices, management recommendations, and a competitive market analysis provided by Compensia. Equity awards are generally granted in the first quarter of each fiscal year, after financial results for the prior fiscal year are available.
The OCC sets the grant value and type of awards granted to our NEOs based on an assessment of the value and type of awards granted by our peers and targets values to be competitive relative to comparable executive positions. Once the grant value is set, the number of shares underlying individual awards is determined based on the grant value, the stock price on the date of grant, and the accounting assumptions in accordance with FASB Accounting Standards Codification Topic 718 (ASC 718). For fiscal 2022, stock options were valued at approximately 22.3% of the stock price on the date of grant.
Page | 36
In setting award levels, the OCC considered competitive market practices and the recommendations provided by Compensia.
Grants to NEOs in 2022 Fiscal Year | ||||||||||||
Name | Stock Options |
RSUs |
Performance Shares | |||||||||
Grant Date Fair Value (1) |
Shares Underlying Options Granted (2) |
Grant Date Fair Value (1) |
RSUs Granted (3) |
Grant Date Fair Value (1) |
Performance Shares Granted (4) | |||||||
Albert G. White III |
$4,625,000 | 50,994 | $-0- | -0- | $4,625,000 | 11,387 | ||||||
Brian G. Andrews |
$925,000 | 10,199 | $-0- | -0- | $925,000 | 2,277 | ||||||
Daniel G. McBride |
$1,250,000 | 13,782 | $-0- | -0- | $1,250,000 | 3,078 | ||||||
Holly R. Sheffield |
$950,000 | 10,474 | $-0- | -0- | $950,000 | 2,339 | ||||||
Gerard H. Warner III (5) |
$625,000 | 6,891 | $625,000 | 1,539 | $-0- | -0- | ||||||
$250,000 | 2,756 | $250,000 | 616 | $-0- | -0- | |||||||
(1) | Amounts represent the grant values approved by the OCC and may vary slightly from the reported grant date fair values (presented in the Summary Compensation Table on page 41) due to mathematical rounding of fractional shares. For a discussion of valuation assumptions, see Note 9, Stock Plans, in our Notes to Consolidated Financial Statements included in our 2022 Annual Report. |
(2) | Stock options granted in fiscal 2022 generally vest ratably, in annual installments, over a four-year period starting on the first anniversary of the date of grant, except the option to purchase 2,756 shares granted to Mr. Warner, which constituted a promotion grant and will vest in equal portions on the third and fourth anniversaries of the date of grant. All options presented have an exercise price of $406.17, which was equal to the closing trading price of a share of our common stock on the date of grant. |
(3) | RSUs granted to Mr. Warner in fiscal 2022 vest over four years, with the 1,539 RSUs awarded as part of his annual grant vesting equally on January 8th in each of 2023, 2024, 2025 and 2026 and the 616 RSUs awarded as part of his promotion grant vesting equally on each of January 8, 2025, and January 8, 2026. |
(4) | Performance shares granted in fiscal 2022 will vest in full at the end of fiscal 2024 if designated performance targets are met. Each performance share constitutes the right to be issued up to 2 shares of our common stock at maximum achievement. Awards granted are presented here at target number of shares to be awarded. |
(5) | Mr. Warners total award value reflects an increase to align with his new responsibilities. The OCC elected to split his award and to make a portion of the awards subject to deferred vesting. Under this split, $500,000 of the approved award value was awarded as options and RSUs vesting in equal portions in each of the third and fourth years after the date of grant. The balance of the time-based equity granted to Mr. Warner vests on our usual schedule over 4 years. |
Time-Vested Equity (Stock Options and RSUs)
The OCC believes that time-vested equity awards have strong retention value while also closely linking executive compensation to stockholder gains. Time-vested equity awards granted to our executive officers, including our NEOs, are made in the form of stock options and/or RSUs. Stock options only have value to the recipient if we also have growth in our stock price, putting a portion of the executive officers compensation at risk of no return, and RSUs provide guaranteed value if the executive officer remains with the Company. Both award types provide the opportunity for long-term gain tied to stockholder returns while also encouraging longevity and stable management for the Company.
Before the date of grant, each executive officer, including the NEOs, can choose to receive their time-vested award as stock options, RSUs, or a 50/50 combination of the two award types. The OCC retains the authority to set awards as it determines appropriate, regardless of such elections, but it believes that soliciting input from our executive officers enhances the retention value of long-term equity compensation.
Page | 37
Our time-vested equity awards generally vest annually in equal portions over a four-year period, but awards outside of the regular grant cycle or for special purposes may have different vesting. In fiscal 2022, a portion of Mr. Warners time-vested equity award was set to vest in equal portions in each of the third and fourth years after the date of grant.
Mr. Warners total award value includes an increase in connection with his promotion to President of CooperVision designed to align his compensation with his new responsibilities and peer compensation for similar roles. For this first year in his new role, the OCC additionally structured his award such that a portion of the total award is subject to the deferred vesting structure described above. This was done to encourage retention in the new role, and future awards to Mr. Warner are expected to follow the usual vesting structure for time-based equity grants to our NEOs.
Performance-Based Equity (Performance Shares)
In fiscal 2022, our NEOs, other than Mr. Warner, received 50% of their total equity grant value in the form of performance-based equity awards, granted as performance shares. (Mr. Warners equity awards will include performance-based awards starting with fiscal 2023.) These awards require achievement of pre-established increases in non-GAAP earnings per share (EPS) over a three-year performance period and are designed to reflect the direct influence of our NEOs on our long-term financial performance.
The OCC has selected growth in compounded, adjusted EPS calculated on a constant currency basis over a three-year period as the performance measure for these awards due to its belief that this measure provides a strong link to stockholder returns. Shares are released under these awards based on a sliding scale between 50% and 200% of target, assuming threshold achievement is met. The target number of shares to be received on vesting of performance shares is set based the grant value of the award and the share price on the date of grant.
In setting criteria for performance shares, the OCC considers our ongoing performance and the level of achievement under prior performance share awards. Target achievement levels are set to require significantly challenging, but attainable, results and reflect high single-digit to low double-digit percentage growth over time. These targets ensure that even achievement at the threshold levels for payout represents solid growth for the Company and stockholders.
The OCC reviews these target achievement levels with Compensia to ensure that they are reasonable and appropriate. The OCC also considers the objectives for long-term growth set by our Board, the Companys historical achievements, and the OCCs goals for executive compensation.
Employee Benefits & Perquisites
Our NEOs are eligible to receive benefits under programs provided to our employees generally, including participation in our 401(k) plan (with matching contributions), benefits under our Retirement Income Plan (a defined benefit plan), and our health, life, and disability insurance programs. Matching contributions to our 401(k) plan for the NEOs are equal to the matching contributions provided to employees generally, matching 50% of employee contributions up to $8,000 (for a maximum benefit of $4,000 per year). Benefits under the Retirement Income Plan are discussed in more detail in the Narrative to the Pension Benefits Table on page 46.
Page | 38
Our NEOs also receive limited perquisites or other personal benefits, generally in the form of automobile allowances, and, in prior years, income attributable to life insurance policies, and some limited reimbursement for partner travel to business functions and relocation assistance. We only provide perquisites or other personal benefits to our executive officers, including our NEOs, in situations where we believe it is appropriate to assist an individual in the performance of his or her duties, to make our executive officers more efficient and effective, and for recruitment and retention purposes.
Executive Employment Agreements
The OCC considers maintaining a stable and effective management team essential to protecting our, and our stockholders, best interests. Accordingly, the Company entered into employment agreements with each of the NEOs (other than Mr. Warner, who was not an NEO at the time) as of November 2018. The employment agreements provide for severance payments on termination of employment for various reasons, including in connection with a change in control. These agreements provide severance benefits that the OCC has determined are competitive with market practice as well as double-trigger severance benefits for a termination in connection with a change in control, which is intended to encourage their continued attention, dedication, and continuity with respect to their roles and responsibilities without the distraction that may arise from the possibility or occurrence of a change of control of Cooper.
Mr. Warner is eligible for change in control severance benefits under our Change in Control Severance Plan adopted on May 21, 2007. This plan provides for payments on termination of employment in connection with a change in control. Mr. Warner is subject to our standard policies regarding severance in the event of termination for reasons other than in connection with a change in control.
All executive agreements and the Change in Control Severance Plan are discussed in more detail in the section titled Potential Payments on Termination or a Change in Control on page 47.
We maintain stock ownership guidelines that require each of our executive officers to maintain a stock ownership level equal to a specific multiple of their annual base salary as set out below.
There is no required time period for the executive officers to achieve the required ownership. While ownership is below the set guideline the executive officers are expected to hold shares acquired from equity awards until the guidelines are met.
In addition to directly held shares, the potential value of vested stock options and unvested RSUs are credited in consideration of whether ownership requirements have been met.
Guideline (as multiple of base salary) | ||
5x base salary Chief Executive Officer |
Must hold 75% of the shares acquired from equity awards, net of taxes and any exercise cost, until guidelines are met. | |
2x base salary - Other Executive Officers |
Must hold 50% of the shares acquired from equity awards, net of taxes and any exercise cost, until guidelines are met. |
Page | 39
As of October 31, 2022, all of our NEOs were in compliance with the applicable stock ownership guidelines.
Tax Deductibility of Compensation
The OCC considers ways to maintain tax deductibility of the compensation for our executive officers, however, the OCC has the discretion to approve, and it is likely that the Company will pay, compensation which will not be deductible under the Internal Revenue Code.
Report of the Organization & Compensation Committee
The Organization & Compensation Committee of the Board has reviewed and discussed the Compensation Discussion and Analysis with management. Based on this review and discussion, the OCC has recommended to the Board that the Compensation Discussion and Analysis be included in this Proxy Statement and incorporated by reference in our Annual Report on Form 10-K for the fiscal year ended October 31, 2022.
ORGANIZATION & COMPENSATION COMMITTEE
Colleen E. Jay (Chair)
William A. Kozy
Teresa S. Madden
Gary S. Petersmeyer
Page | 40
Summary Compensation Table
The table below shows compensation paid during fiscal years 2022, 2021, and 2020 to the individuals who served as our NEOs during the past fiscal year.
Name and Principal Position | Year | Salary ($) |
Bonus (1) ($) |
Stock ($) |
Option ($) |
Non-Equity Incentive Plan Compensation (1) ($) |
Change in ($) |
All
Other ($) |
Total ($) |
|||||||||||||||||||||||||
Albert G. White III |
2022 | $925,000 | $0 | $4,625,058 | $4,625,156 | $1,544,750 | $0 | $16,000 | $11,735,964 | |||||||||||||||||||||||||
President & Chief Executive |
2021 | $925,000 | $375,781 | $4,249,836 | $4,249,824 | $1,127,344 | $51,121 | $16,000 | $10,994,906 | |||||||||||||||||||||||||
Officer |
2020 | $925,000 | $867,188 | $0 | $7,700,008 | $0 | $73,576 | $18,255 | $9,584,027 | |||||||||||||||||||||||||
Brian G. Andrews |
2022 | $541,667 | $0 | $924,849 | $925,049 | $506,567 | $0 | $16,000 | $2,914,132 | |||||||||||||||||||||||||
Executive Vice President, Chief |
2021 | $500,000 | $113,750 | $824,936 | $824,993 | $341,250 | $39,503 | $16,000 | $2,660,432 | |||||||||||||||||||||||||
Financial Officer & Treasurer |
2020 | $500,000 | $243,750 | $0 | $1,475,014 | $0 | $61,739 | $18,259 | $2,298,762 | |||||||||||||||||||||||||
Daniel G. McBride |
2022 | $720,886 | $0 | $1,250,191 | $1,250,027 | $796,435 | $0 | $16,000 | $4,033,539 | |||||||||||||||||||||||||
Executive Vice President & Chief |
2021 | $700,000 | $182,000 | $1,175,170 | $1,174,934 | $546,000 | $59,569 | $16,000 | $3,853,673 | |||||||||||||||||||||||||
Operating Officer |
2020 | $700,000 | $420,000 | $0 | $2,159,972 | $0 | $80,289 | $16,997 | $3,377,259 | |||||||||||||||||||||||||
Holly R. Sheffield |
2022 | $545,869 | $0 | $950,032 | $949,992 | $468,755 | $0 | $15,850 | $2,930,497 | |||||||||||||||||||||||||
President, CooperSurgical, Inc. |
2021 | $525,000 | $119,438 | $875,068 | $874,936 | $358,313 | $39,851 | $16,000 | $2,808,605 | |||||||||||||||||||||||||
2020 | $525,000 | $255,937 | $0 | $1,694,012 | $0 | $37,303 | $34,465 | $2,546,717 | ||||||||||||||||||||||||||
Gerard H. Warner III |
2022 | $437,671 | $0 | $875,296 | $874,983 | $391,595 | $0 | $32,511 | $2,612,056 | |||||||||||||||||||||||||
President, CooperVision, Inc.
|
||||||||||||||||||||||||||||||||||
(1) | Amounts shown in the Non-Equity Incentive Plan Compensation column reflect annual cash incentives earned under the 2022 Incentive Payment Plan. The structure of our Incentive Payment Plan is discussed in more detail below in the narrative discussion following the Grants of Plan Based Awards Table on page 42 and in our Compensation Discussion and Analysis on page 21. |
(2) | Amounts shown in the Option Awards and Stock Awards columns reflect the aggregate grant date fair value of stock option, RSUs, and performance shares granted to each Named Executive Officer in accordance with ASC 718, Compensation-Stock Compensation. Performance share award values are presented at Target achievement. For a discussion of valuation assumptions, see Note 9, Stock Plans, in our Notes to Consolidated Financial Statements included in our 2022 Annual Report. The performance share values as of the grant date, assuming that the highest level of performance is achieved, are: |
Albert G. White III |
$9,250,116 | |
Brian G. Andrews |
$1,849,698 | |
Daniel G. McBride |
$2,500,383 | |
Holly R. Sheffield |
$1,900,063 |
These awards are discussed in more detail below in the narrative discussion following the Grants of Plan Based Awards Table on page 42 and in the Compensation Discussion and Analysis on page 21. |
(3) | Change in value of accumulated pension benefits for the 2022 fiscal year was calculated as the difference between the value of accumulated benefits on October 31, 2022 and the value of accumulated benefits on October 31, 2021. Present value of accumulated benefits at October 31, 2022 are based on a 5.74% discount rate and the Pri-2012 mortality rates with projection scale MP-2021 and the value of accumulated benefits on October 31, 2021 are based on a 2.76% discount rate and the Pri-2012 mortality rates with projection scale MP-2021. |
Page | 41
The accumulated pension value for the NEOs decreased in fiscal 2022 as follows: |
Albert G. White III |
$(189,338) | |
Brian G. Andrews |
$(178,295) | |
Daniel G. McBride |
$(178,773) | |
Holly R. Sheffield |
$(20,661) | |
Gerard H. Warner III |
$(88,536) |
(4) | Amounts included in the All Other Compensation column for fiscal 2022 represent matching contributions under our 401(k) Plan ($4,000) and annual automobile allowance ($12,000) for each of the NEOs. Amounts for Mr. Warner also include personal travel costs ($16,511) for airfare, food, lodging, and other expenses paid in connection with Company events and determined to not be reimbursable expenses under IRS regulations. |
Grants of Plan Based Awards Table
This table presents information regarding the possible awards payable under our 2022 IPP and the value of certain equity awards granted to our NEOs in the 2022 fiscal year. Our equity grant practices and calculation of awards under the 2022 IPP are discussed in more detail below and in the Compensation Discussion and Analysis on page 21.
Estimated Future Payouts Under Non-Equity Incentive Plan
|
Estimated Future Payouts Under
|
All Other Stock or of |
All
Other (#)
|
Exercise
|
Grant Date Fair and Awards (5) ($)
| |||||||||||||||||
Name
|
Grant Date
|
Threshold ($)
|
Target ($)
|
Maximum ($)
|
Threshold (#)
|
Target (#)
|
Maximum (#)
|
Units(3) (#)
| ||||||||||||||
Albert G. White III |
12/7/2021 | $144,531 | $1,156,250 | $2,312,500 | - | - | - | - | - | - |
$0 | |||||||||||
12/7/2021 | - | - | - | - | - | - | - | 50,994 | $406.17 | $4,625,156 | ||||||||||||
12/7/2021 | - | - | - | 5,694 | 11,387 | 22,774 | - | - | - |
$4,625,058 | ||||||||||||
Brian G. Andrews |
12/7/2021 | $48,125 | $385,000 | $770,000 | - | - | - | - | - | - | $0 | |||||||||||
12/7/2021 | - | - | - | - | - | - | - | 10,199 | $406.17 | $925,049 | ||||||||||||
12/7/2021 | - | - | - | 1,139 | 2,277 | 4,554 | - | - | - | $924,849 | ||||||||||||
Daniel G. McBride |
12/7/2021 | $72,506 | $580,048 | $1,160,096 | - | - | - | - | - | - |
$0 | |||||||||||
12/7/2021 | - | - | - | - | - | - | - | 13,782 | $406.17 | $1,250,027 | ||||||||||||
12/7/2021 | - | - | - | 1,539 | 3,078 | 6,156 | - | - | - | $1,250,191 | ||||||||||||
Holly R. Sheffield |
12/7/2021 | $51,567 | $412,532 | $825,065 | - | - | - | - | - | - |
$0 | |||||||||||
12/7/2021 | - | - | - | - | - | - | - | 10,474 | $406.17 | $949,992 | ||||||||||||
12/7/2021 | - | - | - | 1,170 | 2,339 | 4,678 | - | - | - | $950,032 | ||||||||||||
Gerard H. Warner III |
12/7/2021 | $36,563 | $292,500 | $585,000 | - | - | - | - | - | - |
$0 | |||||||||||
12/7/2021 | - | - | - | - | - | - | - | 9,647 | $406.17 | $874,983 | ||||||||||||
12/7/2021 | - | - | - | - | - | - | 2,155 | - | - | $875,296 | ||||||||||||
(1) | Amounts reported in these columns represent the threshold, target, and maximum cash bonus amounts which could have been paid to each NEO under our 2022 IPP, which was approved on December 7, 2021. Target amounts represent the potential bonus that would be paid on 100% achievement of approved goals under the IPP. Threshold amounts represent the minimum achievement necessary for payment on only the lowest weighted quantitative factor. All awards are capped at a maximum of 200% of the target annual performance-based cash incentive opportunity. The final award amounts for the 2022 IPP were approved on December 13, 2022 and are included in Summary Compensation Table on page 41. |
Page | 42
(2) | Amounts represent the threshold, target, and maximum amounts of shares distributable under performance shares granted on December 7, 2021 under our 2007 Long-Term Incentive Plan. Awards will vest on the achievement of specified levels of non-GAAP EPS in the 2024 fiscal year. |
(3) | Stock awards reported in this column were granted as restricted stock units. Awards were granted on December 7, 2021 and vest ratably over four years from the date of grant, other than 616 restricted stock units granted to Mr. Warner, which vest in two equal installments on the third and fourth anniversaries of the date of grant. |
(4) | Option awards reported in this column were granted with an exercise price equal to the closing trading price of our common stock on December 7, 2021 and will expire if not exercised prior to the tenth anniversary of the grant date, or earlier in the event of a termination of employment. These awards will vest ratably over four years from the date of grant, other than the option to purchase 2,756 shares of our common stock granted to Mr. Warner, which vest in two equal installments on the third and fourth anniversaries of the date of grant. |
(5) | Amounts reported in the Grant Date Fair Value of Stock and Option Awards column represent the grant date fair value of the awards granted in the 2022 fiscal year calculated in accordance with ASC 718. For a discussion of valuation assumptions, see Note 9, Stock Plans, in our Notes to Consolidated Financial Statements included in our 2022 Annual Report. |
Page | 43
Outstanding Equity Awards at Fiscal Year End Table
This table provides information regarding the equity award holdings of the NEOs as of the end of the 2022 fiscal year.
Option Awards | Stock Awards | |||||||||||||||||||
Equity Incentive Plan Awards | ||||||||||||||||||||
Name | Award Grant Date |
Number
of (#) |
Number
of (#) |
Option ($) |
Option Expiration Date |
|
Number Shares not (#) |
Market or Units ($) |
Number of Unearned Rights that have Vested (#) |
Market or ($) | ||||||||||
Albert G. White III | 12/13/2016 | 28,748 | 0 | $175.31 | 12/13/2026 | 0 | $0 | 0 | $0 | |||||||||||
12/12/2017 | 17,480 | 4,369 | $229.66 | 12/12/2027 | (3) | 0 | $0 | 0 | $0 | |||||||||||
12/12/2017 | 17,272 | 0 | $229.66 | 12/12/2027 | 0 | $0 | 0 | $0 | ||||||||||||
5/1/2018 | 22,988 | 11,491 | $230.09 | 5/1/2028 | (4) | 0 | $0 | 0 | $0 | |||||||||||
12/11/2018 | 54,356 | 36,236 | $254.77 | 12/11/2028 | (3) | 0 | $0 | 0 | $0 | |||||||||||
12/10/2019 | 43,725 | 65,588 | $304.54 | 12/10/2029 | (3) | 0 | $0 | 0 | $0 | |||||||||||
12/8/2020 | 12,636 | 37,909 | $345.74 | 12/8/2030 | 0 | $0 | 0 | $0 | ||||||||||||
12/8/2020 | 0 | 0 | 12/8/2030 | (7) | 0 | $0 | 6,146 | $1,680,255 | ||||||||||||
12/7/2021 | 0 | 50,994 | $406.17 | 12/7/2031 | 0 | $0 | 0 | $0 | ||||||||||||
12/7/2021 | 0 | 0 | 12/7/2031 | (8) | 0 | $0 | 5,694 | $1,556,683 | ||||||||||||
Brian G. Andrews | 12/9/2015 | 3,356 | 0 | $131.60 | 12/9/2025 | 0 | $0 | 0 | $0 | |||||||||||
12/13/2016 | 2,841 | 0 | $175.31 | 12/13/2026 | 0 | $0 | 0 | $0 | ||||||||||||
12/12/2017 | 3,110 | 776 | $229.66 | 12/12/2027 | (3) | 0 | $0 | 0 | $0 | |||||||||||
12/12/2017 | 1,779 | 0 | $229.66 | 12/12/2027 | 0 | $0 | 0 | $0 | ||||||||||||
12/12/2017 | 0 | 0 | 12/12/2027 | (9) | 108 | $29,526 | 0 | $0 | ||||||||||||
5/1/2018 | 2,874 | 1,436 | $230.09 | 5/1/2028 | (4) | 0 | $0 | 0 | $0 | |||||||||||
12/11/2018 | 10,871 | 7,247 | $254.77 | 12/11/2028 | (3) | 0 | $0 | 0 | $0 | |||||||||||
12/10/2019 | 8,376 | 12,564 | $304.54 | 12/10/2029 | (3) | 0 | $0 | 0 | $0 | |||||||||||
12/8/2020 | 2,453 | 7,359 | $345.74 | 12/8/2030 | 0 | $0 | 0 | $0 | ||||||||||||
12/8/2020 | 0 | 0 | 12/8/2030 | (7) | 0 | $0 | 1,193 | $326,154 | ||||||||||||
12/8/2020 | 0 | 0 | 12/8/2030 | (14) | 1,446 | $395,322 | 0 | $0 | ||||||||||||
12/7/2021 | 0 | 10,199 | $406.17 | 12/7/2031 | 0 | $0 | 0 | $0 | ||||||||||||
12/7/2021 | 0 | 0 | 12/7/2031 | (8) | 0 | $0 | 1,139 | $311,391 | ||||||||||||
Daniel G. McBride | 12/13/2016 | 28,748 | 0 | $175.31 | 12/13/2026 | 0 | $0 | 0 | $0 | |||||||||||
12/12/2017 | 17,480 | 4,369 | $229.66 | 12/12/2027 | (3) | 0 | $0 | 0 | $0 | |||||||||||
12/12/2017 | 17,272 | 0 | $229.66 | 12/12/2027 | 0 | $0 | 0 | $0 | ||||||||||||
12/11/2018 | 19,766 | 13,177 | $254.77 | 12/11/2028 | (3) | 0 | $0 | 0 | $0 | |||||||||||
12/10/2019 | 12,266 | 18,398 | $304.54 | 12/10/2029 | (3) | 0 | $0 | 0 | $0 | |||||||||||
12/8/2020 | 3,494 | 10,480 | $345.74 | 12/8/2030 | 0 | $0 | 0 | $0 | ||||||||||||
12/8/2020 | 0 | 0 | 12/8/2030 | (7) | 0 | $0 | 1,700 | $464,763 | ||||||||||||
12/7/2021 | 0 | 13,782 | $406.17 | 12/7/2031 | 0 | $0 | 0 | $0 | ||||||||||||
12/7/2021 | 0 | 0 | 12/7/2031 | (8) | 0 | $0 | 1,539 | $420,747 | ||||||||||||
Holly R. Sheffield | 6/4/2018 | 13,146 | 4,382 | $226.30 | 6/4/2028 | (5) | 0 | $0 | 0 | $0 | ||||||||||
6/4/2018 | 0 | 0 | 6/4/2028 | (5) | 1,104 | $301,823 | 0 | $0 | ||||||||||||
12/11/2018 | 7,412 | 4,941 | $254.77 | 12/11/2028 | (3) | 0 | $0 | 0 | $0 | |||||||||||
12/11/2018 | 0 | 0 | 12/11/2028 | (10) | 1,177 | $321,780 | 0 | $0 | ||||||||||||
12/10/2019 | 9,620 | 14,429 | $304.54 | 12/10/2029 | (3) | 0 | $0 | 0 | $0 | |||||||||||
12/8/2020 | 2,602 | 7,804 | $345.74 | 12/8/2030 | 0 | $0 | 0 | $0 | ||||||||||||
12/8/2020 | 0 | 0 | 12/8/2030 | (7) | 0 | $0 | 1,266 | $346,112 | ||||||||||||
12/7/2021 | 0 | 10,474 | $406.17 | 12/7/2031 | 0 | $0 | 0 | $0 | ||||||||||||
12/7/2021 | 0 | 0 | 12/7/2031 | (8) | 0 | $0 | 1,170 | $319,866 | ||||||||||||
Gerard H. Warner III | 12/12/2017 | 535 | 0 | $229.66 | 12/12/2027 | 0 | $0 | 0 | $0 | |||||||||||
12/12/2017 | 0 | 0 | 12/12/2027 | (9) | 391 | $106,895 | 0 | $0 | ||||||||||||
12/11/2018 | 3,342 | 3,294 | $254.77 | 12/11/2028 | (3) | 0 | $0 | 0 | $0 | |||||||||||
12/11/2018 | 0 | 0 | $- | 12/11/2028 | (10) | 902 | $246,598 | 0 | $0 | |||||||||||
12/10/2019 | 0 | 0 | $- | 12/10/2029 | (11) | 1,822 | $498,117 | 0 | $0 | |||||||||||
12/8/2020 | 0 | 0 | $- | 12/8/2030 | (12) | 1,898 | $518,894 | 0 | $0 | |||||||||||
12/7/2021 | 0 | 6,891 | $406.17 | 12/7/2031 | 0 | $0 | 0 | $0 | ||||||||||||
12/7/2021 | 0 | 2,756 | $406.17 | 12/7/2031 | (6) | 0 | $0 | 0 | $0 | |||||||||||
12/7/2021 | 0 | 0 | 12/7/2031 | (13) | 1,539 | $420,747 | 0 | $0 | ||||||||||||
12/7/2021 | 0 | 0 | 12/7/2031 | (15) | 616 | $168,408 | 0 | $0 | ||||||||||||
Page | 44
(1) | Except as otherwise noted, each equity award vests as to 25% of the underlying shares on each anniversary of the grant date, subject to continued service with the Company through the applicable vesting date. |
(2) | Market value calculated based on a price per share of $273.39, which was the closing price of our common stock on October 31, 2022. |
(3) | Award vests as to 20% of the underlying shares on each anniversary of the date of grant, subject to continued service with the Company through the applicable vesting date. |
(4) | Award vests as to 33.3% of the underlying shares on each of the third, fourth, and fifth anniversaries of the date of grant, subject to continued service with the Company through the applicable vesting date. |
(5) | Award vests as to 25% of the underlying shares on each of the second, third, fourth, and fifth anniversaries of the date of grant, subject to continued service with the Company through the applicable vesting date. |
(6) | Award vests as to 50% of the underlying shares on each of the third and fourth anniversaries of the date of grant, subject to continued service with the Company through the applicable vesting date. |
(7) | Award vests on achievement of specified levels of growth in earnings per share over a three-year performance period ending October 31, 2023, subject to continued service with the Company through the applicable vesting date. Shares amounts presented at threshold payout, which is 50% of target payout. |
(8) | Award vests on achievement of specified levels of growth in earnings per share over a three-year performance period ending October 31, 2024, subject to continued service with the Company through the applicable vesting date. Shares amounts presented at threshold payout, which is 50% of target payout. |
(9) | Award vests as to 20% of the underlying shares on each of January 8, 2019, January 8, 2020, January 8, 2021, January 8, 2022, and January 8, 2023, subject to continued service with the Company through the applicable vesting date. |
(10) | Award vests as to 20% of the underlying shares on each of January 8, 2020, January 8, 2021, January 8, 2022, January 8, 2023, and January 8, 2024, subject to continued service with the Company through the applicable vesting date. |
(11) | Award vests as to 20% of the underlying shares on each of January 8, 2021, January 8, 2022, January 8, 2023, January 8, 2024, and January 8, 2025, subject to continued service with the Company through the applicable vesting date. |
(12) | Award vests as to 25% of the underlying shares on each of January 8, 2022, January 8, 2023, January 8, 2024, and January 8, 2025, subject to continued service with the Company through the applicable vesting date. |
(13) | Award vests as to 25% of the underlying shares on each of January 8, 2023, January 8, 2024, January 8, 2025, and January 8, 2026, subject to continued service with the Company through the applicable vesting date. |
(14) | Award vests as to 50% of the underlying shares on each of January 8, 2024 and January 8, 2025, subject to continued service with the Company through the applicable vesting date. |
(15) | Award vests as to 50% of the underlying shares on each of January 8, 2025 and January 8, 2026, subject to continued service with the Company through the applicable vesting date. |
Page | 45
Option Exercises and Stock Vested Table
The following table details the number of shares acquired by the NEOs upon vesting of RSUs during the 2022 fiscal year. None of our NEOs exercised stock options and no performance shares vested during fiscal 2022.
|
Stock Awards | |||
Name | Number of Shares Acquired on Vesting |
Value Realized on
Vesting | ||
Albert G. White III |
- | $ - | ||
Brian G. Andrews |
251 | $ 102,569 | ||
Daniel G. McBride |
- | $ - | ||
Holly R. Sheffield |
1,694 | $ 618,897 | ||
Gerard H. Warner III |
2,597 | $1,061,238 | ||
|
Pension Benefits Table
Credited service and value of the accumulated benefits payable to our NEOs as of October 31, 2022 under our Retirement Income Plan (the RIP) at the RIPs normal retirement age of 65 are as follows:
Name | Plan Name | Years of Credited Service |
Present Value of Benefit (1) |
Payments During | ||||
Albert G. White III |
Retirement Income Plan | 15.50 | $277,802 | $-0- | ||||
Brian G. Andrews |
Retirement Income Plan | 15.50 | $152,620 | $-0- | ||||
Daniel G. McBride |
Retirement Income Plan | 16.67 | $389,970 | $-0- | ||||
Holly R. Sheffield (2) |
Retirement Income Plan | 3.33 | $67,047 | $-0- | ||||
Gerard H. Warner III |
Retirement Income Plan | 9.42 | $231,243 | $-0- | ||||
|
||||||||
|
(1) | Present value is calculated as of the October 31, 2022 measurement date and is based on a 5.74% discount rate and the Pri-2012 mortality rates with projection scale MP-2021. |
(2) | As of fiscal year end, Ms. Sheffield had not yet vested in her accrued benefits under the RIP. |
Narrative to Pension Benefits Table
The RIP was adopted in December 1983. The majority of the Companys U.S. employees who work at least 1,000 hours per year and were hired before August 1, 2019 are covered by the RIP. For services performed after December 31, 1988, participants accrue an annual retirement benefit equal to 0.60% of base annual compensation up to $10,000 and 1.20% of annual base compensation which exceeds $10,000 but is not in excess of the applicable annual maximum compensation permitted to be taken into account under Internal Revenue Service guidelines for each year of service. Further, current actively employed participants accrue an annual retirement benefit equal to 1.20% of base annual compensation up to the applicable annual maximum compensation for each year of service in excess of 35 Plan years of service. For service prior to January 1, 1989,
Page | 46
participants accrued an annual retirement benefit equal to 0.75% of base annual compensation up to the Social Security Wage Base in effect that year and 1.50% of base annual compensation in excess of the Social Security Wage Base for each year of service.
Based on the current accumulated benefits for the NEOs, the estimated annual benefits payable under the RIP upon retirement (at the RIPs normal retirement age of 65) are as follows:
Officer | Estimated Annual Benefits Payable |
| ||
Albert G. White III |
$93,941 |
| ||
Brian G. Andrews |
$123,256 |
| ||
Daniel G. McBride |
$78,119 |
| ||
Holly R. Sheffield (1) |
$62,405 |
| ||
Gerard H. Warner III |
$58,389 |
|
(1) | As of fiscal year end, Ms. Sheffield had not yet vested in her accrued benefits under the RIP. |
Potential Payments Upon Termination or a Change in Control
The following table provides estimated payments to our NEOs if a covered termination of employment occurred on October 31, 2022. Values in the table reflect cash severance plus the value of equity awards that would be exercisable or vest and be settled on a termination of employment, but do not reflect the value of accumulated benefits payable under the RIP. Equity award value is calculated based on a price per share of $273.39, which was the closing price of our common stock on October 31, 2022.
|
Termination without Cause / Resignation with Good Reason |
Termination without Cause / Resignation with Good Reason in connection with a Change in Control |
Death / Disability | |||
Albert G. White III |
$11,357,676 | $22,242,608 | $11,598,364 | |||
Brian G. Andrews |
$3,317,887 | $4,456,490 | $4,345,677 | |||
Daniel G. McBride |
$7,626,082 | $11,166,428 | $8,388,452 | |||
Holly R. Sheffield |
$2,823,500 | $3,540,360 | $3,637,629 | |||
Gerard H. Warner III |
$771,909 | $2,106,617 | $2,195,776 |
The receipt of all severance payments and benefits (excluding payments and benefits received upon death or disability) is subject to continued compliance with all obligations to the Company, including under any confidentiality agreement with the Company, and the NEOs execution and delivery of a release of claims in favor of the Company.
Page | 47
Messrs. White, McBride, Andrews, and Ms. Sheffield(1)(4)
Termination Without Cause or Resignation for Good Reason |
Severance payment equal to 24 months of base salary (paid in continuing installments on our ordinary payroll schedule)
Target value of annual cash bonus earned under our IPP for the year in which employment terminates (paid as a lump sum)
Reimbursement of monthly COBRA premiums for up to 24 months
All time-vested equity awards which would have vested within 12 months (or 24 months in the case of Messrs. White and McBride) after the termination date will be accelerated; remainder of unvested awards forfeited immediately upon termination
One year to exercise any outstanding and exercisable stock options, including accelerated options
| |
Termination Without Cause or Resignation for Good Reason in Connection with a Change in Control (2) |
Severance payment equal to 36 months of base salary (paid in continuing installments on our ordinary payroll schedule)
Target value of annual cash bonus under our IPP for the year in which employment terminates (paid in a lump sum)
Reimbursement of monthly COBRA premiums for up to 36 months
All outstanding equity awards will be accelerated, with any performance shares to be paid at the target value (unless otherwise specified in the underlying award agreement)
One year to exercise any outstanding and exercisable stock options, including accelerated options
| |
Termination on Death or Disability (3) |
Target value of annual cash bonus under our IPP, prorated based on the period of service in the IPP plan year prior to executives termination date
Outstanding equity awards accelerated on a monthly pro-rata basis, based on the period of service in the vesting term of the award prior to executives termination date
One year to exercise any outstanding and exercisable stock options, including accelerated options
|
(1) | Executive employment agreements include an Internal Revenue Code (IRS Code) Section 280G best pay provision pursuant to which in the event any payments or benefits received by the NEO would be subject to an excise tax under IRS Code Section 4999, they will receive either the full amount of such payments or a reduced amount such that no portion of the payments is subject to the excise tax, whichever results in the greater after-tax benefit to the executive. |
(2) | Payable in the event of termination of employment without Cause, or resignation with Good Reason, within 3 months prior to or 12 months following a Change in Control (as defined in the relevant agreements). |
(3) | Payable to NEO or their estate, as appropriate. |
(4) | NEOs are also entitled to their accrued benefits under the RIP, as described above under Pension Benefits Table, except that, as of fiscal year end, Ms. Sheffield had not yet vested in her accrued benefits under the RIP. |
Page | 48
Mr. Warner(1)
Termination Without Cause(2) |
Severance payment of approximately 5 months of base salary (paid in continuing installments on our ordinary payroll schedule)
Value of annual cash bonus earned under our Incentive Payment Plan for the year in which employment terminates (paid in a lump sum)
Three months to exercise any currently outstanding and exercisable stock options; outstanding RSUs are forfeit
| |
Termination in Connection with a Change in Control(3) |
Severance payment equal to 12 months of base salary (paid in continuing installments on the Companys ordinary payroll schedule)
Pro rata portion of target value of annual cash bonus earned under our IPP for the year in which employment terminates (paid in a lump sum)
Reimbursement of monthly COBRA premiums for up to 12 months
All outstanding equity awards will be accelerated, with any performance share awards to be paid at the target value (unless otherwise specified in the underlying award agreement)
| |
Termination on Death or Disability (2) |
Target value of annual cash bonus under our IPP, prorated based on the period of service in the IPP year prior to executives termination date
One year to exercise any currently outstanding and exercisable stock options; outstanding RSUs are forfeit
|
(1) | Mr. Warner is also entitled to his accrued benefits under the RIP, as described above under Pension Benefits Table. |
(2) | Payments in the event of termination of employment without Cause not in connection with a Change in Control or due to Mr. Warners death or disability are handled in accordance with severance practices generally applicable to employees and the terms of underlying equity award agreements. In the event of termination without Cause, amounts related to the annual cash bonus paid under our IPP will only be paid if termination occurs after the end of relevant fiscal year. |
(3) | Payable in the event of termination of employment without Cause, or resignation with Good Reason, within 12 months following a Change in Control (as defined in the relevant agreement). |
CEO Pay Ratio
The ratio of our CEOs total annual compensation to the median annual total compensation of all employees excluding the CEO (the CEO Pay Ratio) is a reasonable estimate calculated in a manner consistent with Item 402(u) of Regulation S-K.
To identify the median employee, we evaluated the base salary of all employees globally (other than our Chief Executive Officer) as of October 31, 2021. We believe this measure most reasonably reflects the typical annual compensation of our employee population and was consistently applied for all employees.
For employees paid other than in U.S. dollars, base salary amounts were converted from local currency to USD based on exchange rates on October 31, 2021. We did not exclude any non-U.S. employees under the de minimis or other exceptions set forth in Item 402(u) of Regulation S-K, and we did not make any cost-of-living adjustments. Once the median employee was identified, we calculated the median employees total annual compensation in accordance with the requirements of the Summary Compensation Table.
Page | 49
As calculated, we determined:
| The annual total compensation of our median-paid employee for fiscal 2022 was $34,165. |
| The annual total compensation of our Chief Executive Officer for fiscal 2022 was $11,735,964 (as described above in the Summary Compensation Table on page 41). |
| The ratio of CEO compensation to the annual total compensation of our median employee was 344:1. |
Page | 50
Directors of a publicly traded company have substantial responsibilities and time commitments and, with ongoing changes in corporate governance standards, highly qualified and experienced directors are in high demand; therefore, we seek to provide suitable economic incentives for our directors and to compensate them appropriately for their continued performance, increased responsibilities, and dedication. This compensation applies only to our non-employee directors. Members of the Board who are also our employees receive no additional compensation for their service as directors.
The OCC reviews and recommends compensation amounts for our non-employee directors. The full Board approves compensation based on these recommendations. The OCC considers director responsibilities, compensation practices of our peer companies, and recommendations from Compensia in making non-employee director compensation recommendations to the Board. Compensation levels are reviewed at least annually and modified as the Board considers necessary or appropriate.
Components of Director Compensation
Cash Compensation
In fiscal 2022, our non-employee directors received an annual retainer for their service. Additional annual retainers, in recognition of additional responsibility, were paid to the Chairman of the Board, the independent Lead Director, and the Chair of each committee of the Board.
Annual Retainer: |
||||
Chairman of the Board |
$175,000 | |||
Non-Executive Lead Director |
$70,000 | |||
All Other Non-Employee Directors |
$50,000 | |||
Additional Annual Retainer for Service as a Committee Chair: |
||||
Audit Committee |
$25,000 | |||
Organization & Compensation Committee |
$20,000 | |||
Corporate Governance & Nominating Committee |
$15,000 |
Equity Compensation
Our non-employee directors are eligible to receive annual equity awards in the form of RSUs under the Companys 2020 Long-Term Incentive Plan for non-employee directors (the 2020 Directors Plan).
Grants have a total grant date value of $270,000 (or $283,500 and $297,000 in the case of the Lead Director and Chairman, respectively) and are awarded annually on April 1st. If a non-employee director is appointed or elected after April 1st, then the director will receive a grant on the date of such appointment or election that is
Page | 51
proportionally adjusted to reflect the number of months of actual service on the Board during the first fiscal year of their election or appointment.
Awards vest in full on the first anniversary of the date of grant, except that if a director ends their term of service prior to the vesting date, the number of shares released under the award will be prorated according to the portion of the year actually served and the prorated number of shares will be released on the standard April 1 vesting date. If a directors service was terminated prior to the vesting date for Cause, as defined in the 2020 Directors Plan, the director would immediately forfeit the award.
The following table sets forth the total compensation paid to the non-employee directors for their service on the Board and its committees during the 2022 fiscal year. At present, the non-employee directors are not eligible to participate in our pension programs and no deferred compensation or non-equity incentive plans are available to the non-employee directors.
Name | Fees Earned or Paid in Cash (1) |
Stock Awards (2)(3) | Total | |||
Robert S. Weiss (Chairman) |
$175,000 | $296,895 | $471,895 | |||
William A. Kozy (Lead Director) |
$85,000 | $283,614 | $368,614 | |||
Colleen E. Jay |
$70,000 | $269,905 | $339,905 | |||
Jody S. Lindell |
$54,167 | $269,905 | $324,071 | |||
Cynthia L. Lucchese |
$4,167 | $135,117 | $139,284 | |||
Teresa S. Madden |
$70,833 | $269,905 | $340,738 | |||
Gary S. Petersmeyer |
$50,000 | $269,905 | $319,905 | |||
Maria Rivas, M.D. |
$50,000 | $269,905 | $319,905 |
(1) | Fees earned represent all cash compensation paid to the non-employee directors for their service during the most recent fiscal year. |
(2) | Represents the aggregate grant date fair value of RSUs granted under the 2020 Directors Plan to all of the non-employee directors serving on April 1, 2022, as follows: |
○ | Mr. Weiss, as Chairman of the Board was granted 693 RSUs. |
○ | Mr. Kozy, as Lead Director was granted 662 RSUs. |
○ | Ms. Jay, Ms. Lindell, Ms. Madden, Mr. Petersmeyer, and Dr. Rivas were each granted 630 RSUs. |
Ms. Lucchese also received a prorated grant of 512 RSUs on her appointment to the Board on October 1, 2022.
All awards, including Ms. Luccheses prorated award, will vest in full on April 1, 2023. The amounts shown reflect compensation costs recognized in our financial statements in accordance with ASC 718. For a discussion of valuation assumptions, see Note 9, Stock Plans, in our Notes to Consolidated Financial Statements included in our 2022 Annual Report.
Page | 52
(3) | On October 31, 2022, each non-employee director held the following options and RSU awards: |
Name | Shares Underlying Outstanding Stock Options |
Number of RSUs Outstanding | ||
Robert S. Weiss |
177,202 |
693 | ||
William A. Kozy |
1,766 |
662 | ||
Colleen E. Jay |
1,766 |
630 | ||
Jody S. Lindell |
9,091 |
630 | ||
Cynthia L. Lucchese |
- |
512 | ||
Teresa S. Madden |
- |
630 | ||
Gary S. Petersmeyer |
3,064 |
630 | ||
Maria Rivas, M.D. |
- |
630 |
Mr. Weiss outstanding options include options granted under the 2007 Long Term Incentive Plan for employees while Mr. Weiss served as our Chief Executive Officer.
Stock Ownership Requirements
The Board has adopted stock ownership requirements for non-employee directors. The Board adopted this requirement to strengthen the relationship between director and stockholder interests. Under the current requirements non-employee directors must hold shares of our common stock valued at five (5) times their annual retainer.
Shares held must be free of restrictions to meet ownership requirements, and until the required ownership values are met the non-employee directors must retain 100% of the shares of common stock received on vesting of stock awards or on exercise of stock options. All of the non-employee directors complied with the applicable ownership requirements as of October 31, 2022.
Page | 53
PROPOSAL 1 ELECTION OF DIRECTORS
Our Bylaws require that we have a minimum of six and maximum of eleven directors serving on the Board. All directors are elected annually by a majority of votes cast.
The Board sets the size of the board annually prior to the Annual Meeting and has fixed the number of directors to be elected at the 2023 Annual Meeting at eight.
After many years of dedicated service to the Company and its stockholders, Jody S. Lindell announced her intention to retire from the Board and will not be standing for re-election at the 2023 Annual Meeting.
The Nominees
The nominees presented for election as directors are listed below, along with information regarding when they joined the Board, their present principal occupation, recent business experience, and their service on other companies boards of directors. Each nominee listed below currently serves on the Board and there are no family relationships between any of the nominees, or between the nominees and any of our officers.
Each nominee, if elected, will serve as a director until the next Annual Meeting or until their successor is duly elected and qualified. All of the nominees listed below have given their consent to be named as nominees for election and have indicated their intention to serve if they are elected. The Board does not anticipate that any of the nominees will be unable to serve as a director, but in the event that a nominee is unable to serve, the Board may either propose an alternate nominee or elect to reduce the size of the Board. If an alternative nominee is proposed, proxies will be voted for the alternative nominee.
Director Nominees for Consideration at the Annual Meeting
COMMITTEE MEMBERSHIPS | DEMOGRAPHICS | |||||||||||||||||||
CURRENT DIRECTORS | SINCE | AGE | AUDIT | CGNC | OCC | INDEPENDENT | FINANCIAL EXPERT |
OTHER PUBLIC BOARDS |
GENDER | RACE / ETHNICITY | ||||||||||
Robert S. Weiss (Chairman) |
1996 | 76 | ✓ | -- | ||||||||||||||||
William A. Kozy (Lead Director) |
2016 | 71 | ❖ | ◆ | ✓ | 1 | ||||||||||||||
Colleen E. Jay |
2016 | 60 | ◆ | ❖ | ✓ | 2 | F | |||||||||||||
Cynthia L. Lucchese |
2022 | 62 | ◆ | ◆ | ✓ | ✓ | 2 | F | ||||||||||||
Teresa S. Madden |
2020 | 66 | ❖ | ◆ | ✓ | ✓ | 1 | F | ||||||||||||
Gary S. Petersmeyer |
2013 | 75 | ◆ | ◆ | ✓ | -- | ||||||||||||||
Maria Rivas, M.D. |
2021 | 59 | ◆ | ◆ | ✓ | -- | F | Hispanic | ||||||||||||
Albert G. White III (CEO) |
2018 | 53 |
|
|
|
|
|
-- |
|
|
❖ - Committee Chair ◆ Committee Member
Page | 54
COLLEEN E. JAY
|
JOINED THE BOARD: APRIL 2016
| |
INDEPENDENT DIRECTOR | COMMITTEES: Organization & Compensation Committee (Chair) Corporate Governance & Nominating Committee
|
Ms. Jay has almost 35 years of experience within the consumer goods industry, including over 15 years of experience as a senior executive. She has first-hand experience with leading large, complex international business operations, including direct responsibility for operations in China and Europe, giving her a strong background in international business, including strategy, sales and marketing, regulatory challenges, and cultural differences in various markets. She brings strong operational, consumer branding and global perspective to the Board that assists with understanding and analyzing our markets and global expansion.
Business Experience:
Ms. Jay served as a Global Division President for Procter and Gamble until her retirement in October 2017. Her most recent operational assignment was President, Global Beauty Specialty Business at Procter & Gamble from 2015 where she was responsible for the Wella Professional Salon, Cosmetics, Retail Hair Color, and Fragrance businesses, and the successful divestiture of them.
Prior to that, Ms. Jay led the multi-billion dollar Global Retail Hair Care and Color division of Procter & Gamble from 2012 to 2015 and the Global Female Beauty division from 2010 to 2012. She also served as Vice President & General Manager, Greater China Feminine Care, Personal Cleansing, Oral Care & Entire China Marketing Function, based in Guangzhou, China, from 2006 to 2009, where she was responsible for businesses with a combined value of over $1 billion.
She worked in various positions with Procter & Gamble since July 1985 and has led operational units in the United States, Canada, China, and Switzerland (including leading global businesses) during the course of her career. Ms. Jay has also volunteered at Catalyst, Inc., a non-profit organization dedicated to improving workplace inclusion for women.
Other Directorships and Memberships:
Ms. Jay serves on the board of Treasury Wine Estates (ASX:TWE), a publicly traded company making and selling wine for the global market. She also serves on the board of Beyond Meat, Inc. (NASDAQ: BYND) and is a member of its audit committee.
Page | 55
WILLIAM A. KOZY
|
JOINED THE BOARD: April 2016
| |
VICE CHAIRMAN INDEPENDENT LEAD DIRECTOR |
COMMITTEES: Corporate Governance & Nominating Committee (Chair) Organization & Compensation Committee
|
Mr. Kozy has over 40 years of experience in the medical technology industry. Prior to serving as Chief Operating Officer for Becton Dickinson, key business worldwide leadership assignments included responsibilities for the Biosciences, Diagnostic, and Medical segments of the company. He is the only leader in Becton Dickinson history to have led all three segments of the company in his career. He also brings corporate leadership experience from Becton Dickinson in other areas: innovation systems, company manufacturing, and Becton Dickinsons first ERP implementation. Overall, Mr. Kozy brings depth of general management experience in business strategy, operations, and financial performance to this role. Additionally, he has significant experience in merger and acquisition activity, with integration as an area of executive focus.
Business Experience:
Mr. Kozy served as the Chief Operating Officer of Becton Dickinson (NYSE: BDX) from 2012 until his retirement in 2016, and as its Executive Vice President from 2006 until 2016. He also served as a member of the corporate Leadership Team for Becton Dickinson and in various executive roles since 1988, including Senior Vice President of Company Operations from 1998 until 2002, President of BD Diagnostics from 2002 through 2006, President of the BD Biosciences segment from 2006 to 2009 and head of BD Medical from 2009 through 2011.
Other Directorships and Memberships:
Mr. Kozy is the chairman of the board of directors of LivaNova PLC (NASDAQ: LIVN), a publicly traded medical device company focused on neurological and cardiovascular medicine. He also serves on the nominating and corporate governance committee. He also serves as a senior advisor to McKinsey & Company, a global management firm, with a focus on mergers and acquisitions.
Page | 56
CYNTHIA L. LUCCHESE
|
JOINED THE BOARD: OCTOBER 2022
| |
INDEPENDENT DIRECTOR AUDIT COMMITTEE FINANCIAL EXPERT |
COMMITTEES: Audit Committee Corporate Governance & Nominating Committee
|
Ms. Lucchese brings almost 30 years of experience in senior corporate leadership roles, including almost 20 years of service as a Chief Financial Officer for publicly traded companies. She also has significant experience as a director on public company boards, including audit and corporate governance roles. She is qualified as an Audit Committee Financial Expert under the SEC rules and has experience with the review and analysis of financial statements and operational risk, both through her accounting background and her experience with public company audit committees.
Business Experience:
Ms. Lucchese has served as Chief Strategy Officer for Penske Entertainment Corp (previously Hulman and Company), a subsidiary of Penske Corporation, since November 2020 and she served as Chief Administrative Officer and Chief Financial Officer from November 2014 to November 2020. Previously, she was Senior Vice President and Chief Financial Officer of Hillenbrand (NYSE: HI) from 2008 to 2014. She also served from 2005 to 2007 as Senior Vice President and Chief Financial Officer of Thoratec (NASDAQ: THOR), a medical device company focused on treating advanced stage heart failure, and she held various senior financial positions with Guidant Corporation (NYSE: GDT), now a part of Boston Scientific, from 1994 to 2005. Ms. Lucchese earned her undergraduate degree in accounting and MBA from the Indiana University Kelley School of Business.
Other Directorships and Memberships:
Ms. Lucchese serves on the board of Inari Medical (NASDAQ: NARI), a company focused on treatment of venous thromboembolism and other venous diseases, and she serves on the nominating & corporate governance committee and as chair of the audit committee. She also serves on the board of Beaver-Visitec, Inc., a private company owned by TPG, and serves as chair of the audit committee. In addition, she serves on the Deans Council of the Indiana University Kelley School of Business.
Ms. Lucchese previously served on the board of Hanger, Inc. (NYSE: HNGR), a provider of products and services that assist patients with disabilities or injuries, until its acquisition in October 2022 by Patient Square Capital, where she served on the audit committee, and on the board of Intersect ENT (NASDAQ: XENT) from 2014 until its acquisition by Medtronic, Inc. in 2022, where she served on the nominating & corporate governance committee and as chair of the audit committee. She also served on the board of Brightpoint, Inc. (NASDAQ: CELL) from 2009 until its acquisition by Ingram Micro, Inc. in 2012, where she served as chair of the audit committee and a member of the nominating & corporate governance committee, and on the Investment Board of the Next Level Indiana Fund through September 2022.
Page | 57
TERESA S. MADDEN
|
JOINED THE BOARD: DECEMBER 2020
| |
INDEPENDENT DIRECTOR AUDIT COMMITTEE FINANCIAL EXPERT |
COMMITTEES: Audit Committee (Chair) Organization & Compensation Committee
|
Ms. Maddens extensive experience in financial leadership roles and service with the audit committees of public company boards brings valuable accounting knowledge to the Board. She is also qualified as an Audit Committee Financial Expert under the SEC rules and has experience with the review and analysis of financial statements and operational risk, both through her accounting background and her experience with public company audit committees.
Business Experience:
Ms. Madden served as Executive Vice President and Chief Financial Officer of Xcel Energy, Inc. (NASDAQ:XEL), an electric and natural gas utility, from 2011 until her retirement in 2016. She joined Xcel in 2003 as Vice President, Finance, Customer & Field Operations and was named Vice President and Controller in 2004. Previously, she served as Controller for Rogue Wave Software, Inc. from 2000 to 2003 and as Controller for New Century Energies and Public Service Company of Colorado, predecessor companies of Xcel Energy. Ms. Madden holds a Bachelor of Science in Accounting from Colorado State University and a Master of Business Administration from Regis University.
Other Directorships and Memberships:
Ms. Madden serves on the board of Enbridge, Inc. (NYSE: ENB) and serves on the governance committee and as chair of the audit, finance, and risk committee. She previously served as a director for Peabody Energy Corporation (NYSE: BTU) from 2017 to 2020 where she served on the health, safety, security & environmental committee and as chair of the audit committee.
Page | 58
GARY S. PETERSMEYER
|
JOINED THE BOARD: MARCH 2013
| |
INDEPENDENT DIRECTOR | COMMITTEES: Audit Committee Organization & Compensation Committee
|
Mr. Petersmeyer has served as the CEO or President of four companies in the medical device and pharmaceuticals industry and has over 35 years of industry experience in leadership positions. He has extensive knowledge and experience in global markets, including the United States, Asia, and Europe. His expertise includes financial, research and regulatory strategy, and business development with an emphasis on growth, new product lines, and leadership development. He has extensive experience as a director and has experience with service on compensation and audit committees.
Business Experience:
Mr. Petersmeyer currently serves as a consultant to companies in the pharmaceutical and medical device industries. Most recently he co-founded Aesthetic Sciences Corporation in 2004 and served as the Chief Executive Officer and Chairman until December 2010. Prior to that he served as President and Chief Operating Officer of Pherin Pharmaceuticals, Inc. from 2000 to 2001 and as President and Chief Operating Officer of Collagen Corporation, Inc. from 1995 to 1997 and as Chief Executive Officer from 1997 to 1999. From 1976 to 2000 he served in various management positions for pharmaceutical and medical device companies.
Other Directorships and Memberships:
Mr. Petersmeyer served as a director and member of the compensation and audit committees of Omnicell, Inc. (NASDAQ: OMCL) from January 2007 through February 2019. He also served as director and chairman of the board of Cardica, Inc. (NASDAQ: CRDC) through November 2015. He has previously served on the boards of Visx Incorporated and Roxro Pharmaceuticals prior to their acquisitions. He also served as chairman of the board for Positive Coaching Alliance, a non-profit organization dedicated to improving youth sports.
Page | 59
MARIA RIVAS, M.D.
|
JOINED THE BOARD: JULY 2021
| |
INDEPENDENT DIRECTOR | COMMITTEES: Audit Committee Corporate Governance & Nominating Committee
|
Dr. Rivas brings extensive knowledge of the medical profession as well as significant experience in the medical device and healthcare industry, particularly in the area of womens healthcare. Her background provides the Board with crucial insight into the practical application of our womens healthcare products and the needs of medical practitioners.
Business Experience:
Dr. Rivas currently serves as Global Chief Medical Affairs Officer and Head, Evidence Generation for Pfizer, Inc. (NYSE: PFE). Until September 2022, she served as Chief Medical Officer and Senior Vice President for the healthcare business of Merck KGaA, Darmstadt, Germany (which operates as EMD Serono in the US and Canada) where she led the Global Pharmacovigilance, Medical Affairs and Evidence and Value Development (HEOR) teams in over 90 countries. Dr. Rivas has extensive experience in driving growth and commercialization strategies, global operations, digital transformation, and crisis and risk management in highly regulated industries.
Prior to that, Dr. Rivas served as Senior Vice President of Global Medical Affairs at Merck & Co (MSD), as Vice President of Global Medical Affairs at AbbVie, as Vice President of Oncology, General Medicine and Diagnostic Imaging Medical Affairs at Bayer Healthcare, and in various roles at Eli Lilly including Head of US Womens Health Medical Affairs. Before joining Eli Lilly, Dr. Rivas was in private practice as an endocrinologist in Puerto Rico.
Dr. Rivas obtained a BA in Biochemistry from Brandeis University, Waltham, MA and an MD from Columbia Universitys Vagelos College of Physicians and Surgeons, New York, NY. She completed a residency in Internal Medicine and a fellowship in Endocrinology at NY-Presbyterian Hospital, New York, NY. Dr. Rivas is board certified in Endocrinology, Diabetes and Metabolism.
Other Directorships and Memberships:
Dr. Rivas served as a director for Medidata (NASDAQ: MDSO), a public, mid-cap health technology company, until its successful merger with Dassault Systèmes. She served as a member of the audit and compensation committees for Medidata.
Page | 60
ROBERT S. WEISS
|
JOINED THE BOARD: JANUARY 1996
| |
INDEPENDENT DIRECTOR CHAIRMAN OF THE BOARD
|
As our former Chief Executive Officer and with over 40 years of experience with the Company, Mr. Weiss provides the benefit of personal perspective on our business, awareness of our peers and our industry, and an understanding of the strategic goals for our Company that is important to the Board in making decisions regarding the direction of our business. He provides leadership, extensive knowledge of our Company, and business, operating, and policy experience to our Board.
Business Experience:
Mr. Weiss served as our President from March 2008 and as our Chief Executive Officer from November 2007 until his retirement in May 2018. He also served as President of CooperVision, our contact lens subsidiary, from March 2007 to February 2008. He previously served as our Chief Operating Officer from January 2005 to October 2007 and as Executive Vice President from October 1995 to October 2007. He served as our Chief Financial Officer from September 1989 to January 2005. He served as our Treasurer from 1989 to March 2002. Since joining us in 1977, he has held a number of finance positions both with us and Cooper Laboratories, Inc. (our former parent).
Other Directorships and Memberships:
Mr. Weiss served as a director of Accuray Incorporated (Nasdaq: ARAY), a company that develops, manufactures, and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives, until November 2019. He served on its nominating and governance committee and on its audit committee.
He also served as a member of the Board of Trustees of the University of Scranton in Pennsylvania until May 2021, including service on its finance, advancement, and audit committees.
Page | 61
ALBERT G. WHITE III
|
JOINED THE BOARD: MARCH 2018
| |
PRESIDENT & CHIEF EXECUTIVE OFFICER |
As our current Chief Executive Officer, Mr. White provides the Board with a direct connection to senior management and the benefit of managements perspective on our business and immediate strategic goals. He provides leadership, extensive knowledge of our Company, and insight on the day to day operation of the business.
Business Experience:
Mr. White has served as President & Chief Executive Officer and a member of our Board of Directors since May 2018. Previously, he served as Chief Financial Officer from November 2016 until his appointment as CEO and he also served as Executive Vice President and Chief Strategy Officer, positions he held from December 2015 and July 2011, respectively. From August 2015 to May 2018, Mr. White also directed our womens healthcare business and served as Chief Executive Officer of Cooper Medical Inc., the parent company to CooperSurgical. Previously, he served as Vice President, Investor Relations from November 2007 through March 2013 and as Vice President and Treasurer from April 2006 through December 2012. Prior to joining the Company, Mr. White was a Director with KeyBanc Capital Markets for three years and held a number of leadership positions within KeyBank National Association over the prior eight years.
Other Directorships and Memberships:
Mr. White does not hold any external directorships.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE
FOR
EACH OF THE NOMINEES FOR DIRECTOR PRESENTED ABOVE |
Nominees for director will be elected by a majority of the votes cast in person or by proxy at the Annual Meeting. The number of votes cast FOR a nominee must exceed the number of votes cast AGAINST.
Abstentions and broker non-votes will not be counted as votes cast either for or against the nominee and therefore will not affect the outcome of the director elections.
Page | 62
PROPOSAL 2 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Audit Committee has appointed the firm of KPMG LLP to act as our independent registered public accounting firm and to audit our consolidated financial statements for the fiscal year ending October 31, 2023.
This appointment will continue at the pleasure of the Audit Committee and is presented to the stockholders for ratification as a matter of good governance. In the event that this appointment is not ratified by our stockholders, the Audit Committee will consider that fact when it selects our independent auditor for the following fiscal year.
A representative of KPMG is expected to attend the Annual Meeting with an opportunity to make a statement and/or respond to appropriate questions from stockholders present at the Annual Meeting.
KPMG has served as our independent registered public accounting firm since 1982. The Audit Committee believes that KPMGs tenure as the Companys independent registered public accounting firm provides distinct benefits, as KPMG has obtained significant knowledge and expertise in the Companys global business operations, accounting policies and practices, and internal control over financial reporting. This knowledge:
| Enhances audit quality and effectiveness and provides a framework for effective audit design and planning. |
| Enables efficiencies allowing cost effectiveness in fee negotiations. |
| Avoids disruption and additional education, and the substantial knowledge and familiarity required of a new auditor. |
In considering whether to reappoint KPMG, the Audit Committee considered:
| KPMGs qualifications and global capabilities, including its experience in our industry. |
| The results of the Audit Committees annual assessment of KPMGs performance. |
| KPMGs, and the audit engagement teams, independence including whether the provision of non-audit services provided by KPMG, individually and in aggregate, to the Company during 2022 was compatible with their independence. |
| The quality, timeliness, and candor of KPMGs communications with the Audit Committee and management. |
| The appropriateness of KPMGs fees. |
| KPMGs tenure as our independent registered public accounting firm. |
| The controls and processes in place that help ensure KPMGs continued independence. |
| Any Public Company Accounting Oversight Boards firm inspection reports; and |
| The potential impact of appointing a new independent registered public accounting firm. |
Based on this evaluation, the Audit Committee believes that KPMG is independent, and its selection is in the best interests of the Company.
Page | 63
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE
FOR
THE RATIFICATION OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM |
The proposal to ratify the selection of KPMG LLP as our independent registered public accounting firm for the 2023 fiscal year requires an affirmative vote of the majority of the shares represented in person or by proxy at the Annual Meeting and entitled to vote on the proposal.
Abstentions will have the same practical effect as votes against this proposal. Broker non-votes will have no effect in determining the outcome of this proposal.
Page | 64
PROPOSAL 3 APPROVAL OF THE 2023 LONG-TERM INCENTIVE PLAN
Overview
We are seeking stockholder approval for the 2023 Long-Term Incentive Plan (the 2023 LTIP) as described below.
The 2023 LTIP was adopted by our Board on December 13, 2022, on the recommendation of our OCC and subject to subsequent stockholder approval at the Annual Meeting.
The 2023 LTIP is intended to replace the Third Amended & Restated 2007 Long-Term Incentive Plan (the 2007 Plan). Upon stockholder approval of the 2023 LTIP, the 2023 LTIP will become effective and will supersede and replace in its entirety the 2007 Plan, and no further awards will be granted under the 2007 Plan; however, the terms and conditions of the 2007 Plan will continue to govern any outstanding awards granted under the 2007 Plan. If the 2023 LTIP is not approved by our stockholders, it will not become effective, the 2007 Plan will continue in effect, and we may continue to grant awards under the 2007 Plan, subject to its terms, conditions, and limitations, using the shares available for issuance under the 2007 Plan.
The number of shares available for issuance under the 2023 LTIP is equal to the sum of (i) 1,365,000 shares of common stock, which represents approximately 3% of our outstanding shares of common stock as of the Record Date, (ii) any shares of common stock, which as of the effective date of the 2023 LTIP, are available for issuance under the 2007 Plan, and (iii) any shares of common stock that are subject to awards under the 2007 Plan that become available for issuance under the 2023 LTIP in accordance with the terms of the 2023 LTIP, as described in more detail below.
Consistent with our commitment to good compensation governance, the 2023 LTIP reflects various best practices, as described in more detail below.
Employees and consultants of the Company, or any subsidiary of the Company, are eligible to receive awards under the 2023 LTIP. The 2023 LTIP provides for the grant of stock options, including incentive stock options (ISOs) and nonqualified stock options (NSOs), stock appreciation rights (SARs), restricted stock, restricted stock units (RSUs), performance shares, and other stock or cash-based awards to eligible individuals.
Approval of the 2023 LTIP will constitute approval pursuant to the stockholder approval requirements of the NYSE and Section 422 of the IRS Code, relating to ISOs.
The full text of the proposed 2023 LTIP is attached as Exhibit A. The following general description of certain features of the 2023 LTIP is qualified in its entirety by reference to the plan document.
Key Features of the 2023 LTIP
The 2023 LTIP reflects a broad range of compensation and governance best practices, as highlighted below. These features are intended to align our equity compensation practices with current best practices.
| Automatic acceleration of awards only if not assumed or substituted in connection with a Change in Control (as defined in the 2023 LTIP). |
| Prohibition of liberal stock recycling on stock options and SARs. The 2023 LTIP prohibits (i) any shares tendered or withheld in payment of the exercise price of a stock option, and (ii) shares subject to a SAR or |
Page | 65
other stock-settled award that are not issued in connection with the settlement or exercise of the award from being added back to the share reserve. |
| No dividend equivalents paid on outstanding awards. Dividends are paid with respect to restricted stock only after the shares of restricted stock vest. |
| No repricing of stock options or SARs without stockholder approval. Under the 2023 LTIP, stock options and SARs may not be repriced, replaced or regranted through cancellation or modification without stockholder approval if the effect would be to reduce the exercise price for the shares under the award. |
| No evergreen feature/stockholder approval required for stock reserve increases. The 2023 LTIP does not provide for an annual increase in the share reserve, and the 2023 LTIP may not be amended to increase the share reserve without stockholder approval. |
Summary of Terms
Administration
The 2023 LTIP may be administered by the Board, the OCC or another committee designated by the Board. To the extent required to comply with Rule 16b-3 of the Exchange Act, it is intended that each member of such committee will be a non-employee director within the meaning of Rule 16b-3. The committee or our Board may delegate its powers under the 2023 LTIP to one or more members of the Board or one or more directors or officers of the Company, provided that no officer may be delegated the authority to grant awards to or amend awards held by senior executives of the Company who are subject to Section 16 of the Exchange Act or any officer or director to whom authority to grant or amend awards has been delegated. The Board, OCC, or delegate thereof, as applicable, are referred to in this proposal as the Administrator.
The Administrator has the authority to administer the 2023 LTIP, including the power to determine eligibility, the types and sizes of awards, the price and vesting schedule of awards, the methods for settling awards, the method of payment for any exercise or purchase price, any rules and regulations the Administrator deems necessary to administer the 2023 LTIP, and the acceleration or waiver of any vesting restriction.
Eligibility
Persons eligible to participate in the 2023 LTIP include approximately 650 employees (including seven executive officers), and various consultants of the Company and its subsidiaries, in each case, as determined by the Administrator.
Shares subject to the 2023 LTIP
If our stockholders approve the 2023 LTIP, the number of shares available for issuance under the 2023 LTIP will be equal to the sum of (i) 1,365,000 shares of common stock, which represents approximately 3% of our outstanding shares of common stock as of the Record Date, (ii) any shares of common stock, which as of the effective date of the 2023 LTIP, are available for issuance under the 2007 Plan, and(iii) any shares of common stock that are subject to awards under the 2007 Plan that are forfeited or expire, are converted to shares of another person in connection with a recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, exchange of shares or other similar event, or 2007 Plan award is settled for cash (in whole or in
Page | 66
part) (including unvested shares of restricted stock repurchased by the Company at the same price paid by the grantee). The shares issued pursuant to an award under the 2023 LTIP may be authorized but unissued shares, shares purchased by the Company on the open market or treasury shares.
If any shares of common stock that are subject to awards under the 2023 LTIP (or, as described above, the 2007 Plan) are forfeited or expire, are converted to shares of another person in connection with a recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, exchange of shares or other similar event, or are settled for cash (in whole or in part) (including unvested shares of restricted stock repurchased by the Company at the same price paid by the grantee), any shares subject to such award may, to the extent of such forfeiture, expiration or cash settlement, be used again for new grants under the 2023 LTIP. However, the following shares may not be used again for grant under the 2023 LTIP: (i) shares tendered or withheld in payment of the exercise price of an option granted under the 2023 LTIP or 2007 Plan, (ii) shares subject to a SAR or other stock-settled award under the 2023 LTIP or 2007 Plan that are not issued in connection with the exercise or stock settlement, as applicable, of the award; and (iii) shares purchased on the open market with the cash proceeds from the exercise of stock options under the 2023 LTIP or 2007 Plan. Awards granted under the 2023 LTIP in connection with the assumption or substitution of outstanding equity awards previously granted by a company or other entity in the context of a corporate acquisition or merger will not reduce the shares authorized for grant under the 2023 LTIP.
Types of Awards
The 2023 LTIP provides for the grant of ISOs, NSOs, SARs, restricted stock, RSUs, PSUs, and other stock or cash-based awards. All awards under the 2023 LTIP will be set forth in award agreements, which will detail all terms and conditions of the awards, including any applicable vesting and payment terms and post-termination exercise limitations. Vesting conditions determined by the Administrator may include continued service, attainment of performance goals and/or other conditions. No fractional shares shall be issued or delivered pursuant to the 2023 LTIP or any award thereunder, unless otherwise determined by the Administrator.
Options
Stock options provide for the purchase of shares of common stock in the future at an exercise price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the IRS Code are satisfied. The exercise price of an option may not be less than 100% of the fair market value of the underlying stock on the date of grant (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain substitute stock options granted in connection with a corporate transaction. The term of an option may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders). Unless otherwise provided by the Administrator or otherwise directed by the participant, each vested and in-the-money option will be automatically exercised on the last business day prior to the expiration of its original term.
Stock Appreciation Rights
SARs entitle their holder, upon exercise, to receive an amount equal to the appreciation of the shares subject to the award between the grant date and the exercise date. The exercise price of a SAR may not be less than 100%
Page | 67
of the fair market value of the underlying stock on the date of grant (except with respect to certain substitute SARs granted in connection with a corporate transaction) and the term of a SAR may not be longer than ten years. SARs under the 2023 LTIP will be settled in cash or shares, or in a combination of both, as determined by the Administrator. Unless otherwise provided by the Administrator or otherwise directed by the holder, each vested and in-the-money SAR will be automatically exercised on the last business day prior to the expiration of its original term.
Restricted Stock
A restricted stock award is an award of nontransferable shares of common stock that remains forfeitable unless and until specified vesting conditions are met. In general, restricted stock may not be sold or otherwise transferred until restrictions are removed or expire. Holders of restricted stock will have voting rights and will have the right to receive dividends; however, dividends may not be paid until the applicable shares of restricted stock vest.
Restricted Stock Units and Performance Stock Units
RSUs are contractual promises to deliver shares of common stock (or the fair market value of such shares in cash) in the future, which may also remain forfeitable unless and until specified vesting conditions are met. RSUs generally may not be sold or transferred until vesting conditions are removed or expire. The shares underlying RSUs will not be issued until the RSUs have vested, and recipients of RSUs will have no voting or dividend rights prior to the time the RSUs are settled in shares. Delivery of the shares underlying RSUs may be deferred under the terms of the award or at the election of the participant, if the Administrator permits such a deferral. On the settlement date or dates, the Company will issue to the participant unrestricted, fully transferable shares of common stock (or the fair market value of one such shares in cash) in respect of the vested RSUs.
PSUs are denominated in a number of shares of common stock or in unit equivalents of shares of common stock or units of value (including a dollar value of shares) and may be linked to any one or more of performance or other specific criteria, including service to the Company or its subsidiaries, determined to be appropriate by the Administrator, in each case on a specified date or dates or over any period or periods determined by the Administrator.
Other Stock or Cash-Based Awards
Other stock or cash based awards are awards of cash, fully vested shares of common stock and other awards valued wholly or partially by referring to, or otherwise based on, our common stock. Other stock or cash-based awards may be granted to participants and may also be available as a payment form in the settlement of other awards, as standalone payments and as payment in lieu of base salary, bonus, fees, or other cash compensation otherwise payable to any individual who is eligible to receive awards. The Administrator will determine the terms and conditions of other stock or cash-based awards, which may include vesting conditions based on continued service, performance and/or other conditions.
Transferability
Awards under the 2023 LTIP are generally not transferable, other than for estate or tax planning purposes or pursuant to a domestic relations order.
Page | 68
Adjustments Upon Certain Events
In the event of a stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of assets or any other corporate event affecting the common stock or the share price of the common stock other than an equity restructuring, the Administrator may make equitable adjustments to reflect such change with respect to: (i) the aggregate number and types of shares of stock that may be issued under the 2023 LTIP ; (ii) the number and kind of shares subject to outstanding awards; (iii) the terms and conditions of any outstanding awards (including any applicable performance goals); and/or (iv) the grant or exercise price for any outstanding awards.
In addition, in such a case as noted above or in the event of any unusual or nonrecurring transactions or events affecting the Company or the financial statements of the Company, or of changes in applicable laws, the Administrator, may, in its discretion, subject to the terms of the 2023 LTIP, take any of the following actions if it determines that such action is appropriate in order to prevent the dilution or enlargement of benefits or potential benefits intended to be made available under the 2023 Plan or with respect to any award: (i) provide for either the payment and termination of the award; (ii) provide that the awards shall be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by similar awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and prices; (iii) make adjustments in the number and type of shares of stock (or other securities or property) subject to outstanding awards and/or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding awards that may be granted in the future; (iv) provide for the acceleration of vesting or exercisability of the awards; (v) replace such Awards with other rights or property selected by the Administrator; and/or (vi) provide that the awards cannot vest or be exercised after the event that triggers the action.
If a Change in Control (as defined in the 2023 LTIP), occurs all outstanding options and SARs that are not exercised shall be assumed or substituted by the surviving corporation and other outstanding awards shall be converted into similar awards of the surviving corporation. If the surviving corporation refuses to assume or substitute for an award, the award shall accelerate and become fully vested and exercisable upon the Change in Control and all restrictions on the award shall lapse.
Notwithstanding any other provision of the Plan, if a Change in Control occurs and the outstanding awards are not continued, converted, assumed, substituted or replaced by the surviving or successor entity in such Change in Control, then immediately prior to the Change in Control, the outstanding awards, to the extent not continued, converted, assumed, substituted or replaced, will become fully vested and, as applicable, exercisable, and all forfeiture, repurchase and other restrictions on the awards will lapse immediately prior to such transaction; provided, that, to the extent the vesting of any award is subject to the satisfaction of specified performance goals, the award will vest at the higher of (i) the target level of performance or (ii) the actual performance level as of the date of the Change in Control (as determined by the Administrator) with respect to all open performance periods.
In the event an award continues in effect or is assumed or an equivalent award substituted, and a holder incurs a termination of service without cause (as defined by the Administrator) upon or within 12 months following the Change in Control, then the holder will be fully vested in such continued, assumed or substituted award.
Page | 69
Amendment and Termination
The 2023 LTIP may be amended, modified, or terminated at any time and from time to time; provided that, no amendment, suspension, or termination of the 2023 LTIP shall, without the consent of the holder, materially and adversely affect any rights or obligations under any award, unless the award itself otherwise expressly so provides or such action is to comply with the requirements of Section 409A of the IRS Code.
Notwithstanding the foregoing, the 2023 LTIP requires us to obtain stockholder approval within 12 months before or after doing any of the following (other than in connection with certain corporate events, as described above):
| Increasing the maximum number of shares available under the 2023 LTIP; |
| Reducing the price per share of any outstanding option or SAR granted under the 2023 LTIP; and |
| Cancelling any option or SAR in exchange for cash or another option or SAR having a lower per share exercise price. |
In addition, subject to applicable law and the limitations above, the Administrator may amend, modify, or terminate any outstanding award, including substituting another award of the same or a different type, changing the date of exercise or settlement, and converting an ISO to an NSO. The holders consent to such action will be required unless (a) the Administrator determines that the action, taking into account any related action, would not materially and adversely affect the holder, or (b) the change is otherwise permitted under the 2023 LTIP.
Expiration Date
The 2023 LTIP will expire on, and no award will be granted pursuant to the 2023 LTIP after the tenth anniversary of the date the 2023 LTIP was approved by the Board. Any award outstanding on the expiration date of the 2023 LTIP will remain in force according to the terms of the 2023 LTIP and the applicable award agreement.
U.S. FEDERAL INCOME TAX CONSEQUENCES
This discussion regarding U.S. federal income tax consequences is intended for the general information of our stockholders, not 2023 LTIP awardees. Alternative minimum tax and state and local income taxes are not discussed and may vary depending on individual circumstances and from locality to locality.
IRS Code Section 162(m)
Under IRS Code Section 162(m), income tax deductions of publicly-traded companies may be limited to the extent total compensation (including, without limitation, base salary, annual bonus, RSU settlement and nonqualified benefits) for certain executive officers exceeds $1 million (less the amount of any excess parachute payments as defined in IRS Code Section 280G) in any one year. Under the tax rules in effect before 2018, the IRS Code Section 162(m) deduction limit did not apply to qualified performance-based compensation that was established by an independent compensation committee and conformed to certain restrictive conditions stated under the IRS Code and related regulations. However, the U.S. Tax Cuts and Jobs Act of 2017 eliminated this performance-based compensation exception effective January 1, 2018, subject to a special rule that grandfathers certain awards and arrangements that were in effect on or before November 2, 2017. As a result, compensation awarded under the 2019 Plan in excess of $1 million to our current and former NEOs generally is not deductible.
Page | 70
IRS Code Section 409A
Certain awards under the 2023 LTIP may be considered nonqualified deferred compensation subject to IRS Code Section 409A, which imposes additional requirements on the payment of deferred compensation. These requirements generally provide that, if at any time during a taxable year a nonqualified deferred compensation plan fails to meet the requirements of IRS Code Section 409A or is not operated in accordance with those requirements, all amounts deferred under the nonqualified deferred compensation plan for the then-current taxable year and all preceding taxable years, by or for any awardee with respect to whom the failure relates, are includible in the gross income of the awardee for the taxable year to the extent not subject to a substantial risk of forfeiture and not previously included in gross income. If a deferred amount is required to be included in income under IRS Code Section 409A, the amount will be subject to income tax at regular income tax rates plus a 20 percent penalty, as well as potential premium interest tax.
Federal Tax Treatment of Award Types
With respect to NSOs, the Company is generally entitled to deduct and the optionee recognizes taxable income in an amount equal to the difference between the option exercise price and the fair market value of the shares at the time of exercise. A participant receiving ISOs will not recognize taxable income upon grant. Additionally, if applicable holding period requirements are met, the participant will not recognize taxable income at the time of exercise. However, the excess of the fair market value of the common stock received over the option price is an item of tax preference income potentially subject to the alternative minimum tax. If stock acquired upon exercise of an ISO is held for a minimum of two years from the date of grant and one year from the date of exercise, the gain or loss (in an amount equal to the difference between the fair market value on the date of sale and the exercise price) upon disposition of the stock will be treated as a long-term capital gain or loss, and the Company will not be entitled to any deduction. If the holding period requirements are not met, the ISO will be treated as one which does not meet the requirements of the IRS Code for ISOs and the tax consequences described for NSOs will apply.
The current federal income tax consequences of other awards authorized under the 2023 LTIP generally follow certain basic patterns: SARs are taxed and deductible in substantially the same manner as NSOs; nontransferable restricted stock subject to a substantial risk of forfeiture results in income recognition equal to the excess of the fair market value over the price paid, if any, only at the time the restrictions lapse (unless the recipient elects to accelerate recognition as of the date of grant); stock-based performance awards and other types of awards are generally subject to tax at the time of payment. Compensation otherwise effectively deferred is taxed when paid.
In each of the foregoing cases, the Company will generally have a corresponding deduction at the time the participant recognizes income, subject to Section 162(m) with respect to our current and former NEOs.
Page | 71
Other Information
Additional information regarding the 2023 LTIP, the 2007 Plan, and our other equity award plans, as of October 31, 2022, can be found below.
Overhang
The following table provides information about our equity incentive plans as of the Record Date.
As of January 19, 2023 | ||||
Total shares of Common Stock outstanding |
49,425,340 | |||
Closing price of our Common Stock on the Record Date |
$342.39 | |||
2007 Plan |
||||
Total shares remaining available for grant (1) |
445,531 | |||
Total number of shares subject to outstanding stock options |
1,127,947 | |||
Total number shares subject to outstanding full value awards (1) |
452,694 | |||
All Equity Plans |
||||
Total number of shares subject to outstanding stock options |
1,147,802 | |||
Weighted-average exercise price of outstanding stock options |
$269.97 | |||
Weighted-average remaining term of outstanding stock options |
6.24 years | |||
Total number shares subject to outstanding full value awards (1) |
457,711 | |||
Total shares remaining available for grant (1)(2) |
1,426,457 | |||
(1) | Full value awards include awards to our executive officers and non-executive employees in the form of restricted stock units and performance shares. Outstanding performance shares are subject to increases in our non-GAAP earnings per share over a three-year period and do not yet have a defined payout. Values in this table for shares remaining are presented using the maximum level of achievement opportunity. |
(2) | Total shares available for grant under all equity plans includes 445,531 shares available under the 2007 Plan, 32,836 shares available for grant under the 2020 Directors Plan, and 948,090 shares available under the 2019 Employee Stock Purchase Plan. |
New Plan Benefits Table
Awards made under the 2023 LTIP will be at the discretion of the Administrator. Awards under the 2007 Plan and the 2020 Directors Plan may also be discretionary. Therefore, the amount of any awards that may be made cannot be determined at this tim